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Neuromuscular disorders change the underlying structure and function of motor units within a 
muscle, and are detected using needle electromyography. Currently, inferences about the presence or 
absence of disease are made subjectively and are largely impression-based. Quantitative 
electromyography (QEMG) attempts to improve upon the status quo by providing greater levels of 
precision, objectivity and reproducibility through numeric analysis, however, their results must be 
transparently presented and explained to be clinically viable. 
The probabilistic muscle characterization (PMC) model is ideally suited for a clinical decision 
support system (CDSS) and has many analogues to the subjective analysis currently used. To improve 
disease characterization performance globally, a hierarchical classification strategy is developed that 
accounts for the wide range of MUP feature values present at different levels of involvement (LOI) of 
a disorder. To improve utility, methods for detecting LOI are considered that balance the accuracy in 
reporting LOI with its clinical utility. Finally, several aggregation methods that represent commonly 
used human decision-making strategies are considered and evaluated for their suitability in a CDSS. 
Four aggregation measures (Average, Bayes, Adjusted Bayes, and WMLO) are evaluated, that offer a 
compromise between two common decision making paradigms: conservativeness (average) and 
extremeness (Bayes). 
Standard classification methods have high specificity at a cost of poor sensitivity at low levels of 
disease involvement, but tend to improve with disease progression. The hierarchical model is able to 
provide a better balance between low-LOI sensitivity and specificity by providing the classifier with 
more concise definitions of abnormality due to LOI. Furthermore, a method for detecting two discrete 
levels of disease involvement (low and high) is accomplished with reasonable accuracy. The average 
aggregation method offers a conservative decision that is preferred when the quality of the evidence is 
poor or not known, while the more extreme aggregators such as Bayes rule perform optimally when 
the evidence is accurate, but underperform otherwise due to outlier values that are incorrect. 
The methods developed offer several improvements to PMC, by providing a better balance between 
sensitivity and specificity, through the definition of a clinically useful and accurate measure of LOI, 
and by understanding conditions for which each of the aggregation measures is better suited. These 
developments will enhance the quality of decision support offered by QEMG techniques, thus 
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Neuromuscular disorders change the underlying structure and activation of motor units (MUs) within 
a muscle, thus altering the electrophysiological characteristics of detected electromyographic (EMG) 
signals. A needle EMG examination is a diagnostic test used to investigate these disease-related 
changes.  Currently, any inference or decision based on the acquired signals is usually accomplished 
subjectively, and is driven by the expert knowledge of the physician. While there is a small degree of 
reliance on the most rudimentary forms of quantitative analysis (that is, simply the reporting of 
numerical figures), diagnosis is usually impression-based and must be made in conjunction with 
several other diagnostic tests. Quantitative Electromyography (QEMG) is the process of extracting 
numeric information related to the morphology and activation of MUs from electromyographic 
(EMG) signals (Stashuk and Brown, 2002). The increased level of precision and reproducibility 
obtained by using QEMG makes it useful for exploration of the underlying structure and operation of 
the peripheral neuromuscular control system. Thus, quantitative techniques make it possible to 
objectively characterize muscle tissue with respect to the presence or absence of disease or distress, 
and form the basis for clinical decision support. 
Recent advances in QEMG techniques have resulted in the quantization of important aspects of 
needle EMG examinations, resulting in a more precise numerical and statistical representation of their 
results (Stashuk and Brown, 2002; Stashuk, 1999; Stashuk, 2001; Doherty and Stashuk, 2003; McGill 
et al., 1991; Pino et al., 2010; Pino, 2009; Pino et al., 2008). The more sophisticated of these methods 
provide interpreted muscle characterizations that support the decision making process. However, 
despite the advent of quantitative techniques and the prevalence of decision support in the general 
field of medicine, QEMG practices remain in their infancy. One of the main impediments to the wide-
spread acceptance of QEMG techniques is the inherent difficulty of presenting vast amounts of 
quantified data in a way that can be easily interpreted. Human decision makers have difficulty 
interpreting and mentally comparing numeric information without the necessary context or level of 
explanation. Such shortcomings of quantified data highlight a specific characteristic that decision 
support and QEMG methods must possess, namely transparency. A system that can explain its 
conclusions in a manner that is consistent with, and analogous to, the cognitive processes employed 
by a human decision maker, can thus improve upon the quality and accuracy of any inferences made 
by the clinician. 
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The current state of the art in QEMG is the probabilistic muscle characterization (PMC) framework 
presented in this work and others (Pino et al., 2010; Pino et al., 2008; Pino et al., 2008; Hamilton-
Wright et al., 2010; Pino et al., 2008). The key benefit of quantitative methods and PMC in particular, 
is that they offer greater objectivity and consistency over their subjective counterparts. Providing 
physicians with objective quantitative information that is supplementary to the information currently 
obtained from clinical tests can reduce the ambiguity in the diagnosis and treatment of disorders, and 
provide a higher level of precision and detail. Specifically, measures of confidence or confusion 
surrounding a particular decision, and information about the types of errors and quality of data make 
it possible to consider the entire decision making workflow, while providing a transparent explanation 
of the underlying mechanisms involved in deciding on a course of action. Additionally, the ability to 
report a richer set of information allows the decision maker to gain insight into the level of 
involvement (LOI) of disease, allowing clinicians to manage and treat its progression over time.  
Moreover, the PMC framework, as will be seen, provides a quantitative analogue to current clinical 
practice. By providing a decision-making framework that mimics the cognitive processes of a human 
decision maker facilitates easier adoption of, and trust in, such systems by clinicians.  
These latter aspects of decision support and QEMG form the fundamental motivation for the 
current work. In particular, building on the probabilistic muscle characterization framework 
developed by Pino (Pino, 2009; Pino et al., 2010) and others, the optimal configuration and form of 
the system is sought. Specific objectives pertaining to these areas include the following:  
1. A decision-making (aggregating) scheme is desired that balances the trade-off between 
sensitivity and specificity. 
2. The definition and clinical utility of a measure of LOI is sought. 
3. The validity of these methods applied to real-world data is to be evaluated. 
A clinically viable decision support system centered on the PMC framework is to be further 





Overview of the Thesis 
The contents of this thesis are dedicated to achieving the above-mentioned goals as follows. 
Chapter 2 will provide the reader with the necessary background in neuromuscular disease, clinical 
electromyography, QEMG, and decision support in order to appreciate the methods described herein. 
Chapter 3 will present the probabilistic muscle characterization framework in the context of 
decision support, and will highlight the key areas that are being further developed in this work. The 
data sets used in evaluating and validating the methods developed are then presented in Chapter 4, 
along with a brief statistical analysis in order to build a case for using more advanced techniques.  
Chapter 5 describes the methods developed in this work in order to improve the accuracy of disease 
and LOI characterization, as well as the techniques used in evaluating their performance. Chapter 6 
will present the results generated by evaluating the methods, with a focus on those techniques that 
optimize the abovementioned goals. Following that, Chapter 7 discusses the results in terms of their 
relevance for clinical use, and highlights any shortcomings of the methods.  
Finally, Chapter 8 concludes the work by summarizing the relevant findings and assessing whether 
or not they meet the goals outlined in the introduction. A special sub-section will make note of 
recommended future work, that the author feels is necessary in order to adopt the developed system 
for clinical use. 
Appendix A provides supplementary material pertaining to derivations of certain equations or 
mathematical background material that is not well-suited for the background section of this thesis.  
Appendix B presents screen-shots of a decision support system implementation based on the 





2.1 Physiology and Neuromuscular Disease 
The smallest functional unit of muscle is termed the motor unit (MU), and consists of a group of 
localized muscle fibers (MFs) that are innervated by a single neuron in the spinal cord. MUs are 
recruited (activated) by the central nervous system according to Henneman's Size Principle1 and it is 
the combination of the firing frequency of each MU, as well as the number and size of active MUs, 
that determine the amount of force exerted by the muscle. Contraction of muscle fibers is preceded by 
the initiation of action potentials in the end plate region and subsequent spread of the potentials along 
the surface of the sarcolemmal membranes toward the musculo-tendinous junctions of the muscle 
fibers. The currents associated with these action potentials spread throughout the extracellular space 
surrounding the muscle fibers and create time varying voltage fields (Stashuk and Brown, 2002). 
The latter field potentials can be detected by needle electrodes positioned in the extracellular space 
and the resulting waveform measurements form the basis of needle electromyography. Waveforms 
generated by action potentials of single muscle fibers (MF) are called muscle fiber potentials (MFPs) 
whereas waveforms associated with the electrical activity of whole motor units (MU) are called motor 
unit potentials (MUPs). The successive, semi-rhythmic MUPs generated by an active MU are referred 
to as motor unit potential trains (MUPT) and are often represented by a single aggregate MUP 
template with similar characteristics. The collection of waveforms detected during the contraction of 
a muscle is termed an electromyographic (EMG) signal and represents the spatial and temporal 
summation of all contributing MUPTs as well as baseline noise. 
Neuromuscular disorders (NMD) change the morphology and activation patterns of the MUs of the 
muscles affected. There are two major categories of NMD: those that affect the nervous system are 
termed neurogenic (e.g., Lou Gehrig’s disease), while those that affect the muscle tissue are referred 
to as myopathic (e.g., Muscular Dystrophy). As depicted in Figure 2.1, myopathic disorders in 
general maintain the number of MUs in a muscle but reduce the number of muscle fibers in the MUs 
                                                    
1
 Henneman's size principle states that motor units are generally recruited in order of smallest to largest (fewest 
fibers to most fibers) as contraction increases. An electromyographer must be aware of this when sampling 
MUs because inconsistent contraction levels may introduce abnormally large or small MUPs resulting in 
possible data misinterpretation. 
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due to atrophy and eventual fiber necrosis. At the same time, other fibers may hypertrophy thus 
increasing the range of fiber diameters and motor unit fiber densities in the MUs. To compensate for 
fiber loss and fiber diameter changes, MU recruitment and firing rate are higher in myopathic muscle 
then in healthy muscle in order to create a specific level of contraction.  In contrast, neurogenic 
disorders in general cause a loss of motoneurons or innervation, resulting in fewer MUs.  However, 
denervated fibers are reinnervated by axonal sprouts of surviving MUs resulting in muscles with 
fewer MUs but with MUs that have larger territories, larger numbers of fibers, and uneven motor unit 
fiber densities compared to healthy muscles.  These MU fiber changes are also depicted in Figure 2.1.  
As a result of MU loss and reinnervation, fewer MUs are required to be recruited in neurogenic 





Figure 2.1: Effects of disease on motor unit morphology and motor unit potentials 
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2.2 Clinical Electromyography 
EMG signals provide a unique insight into both the structure and function of muscle tissue.  The fiber 
and MU activation changes caused by a disorder are reflected in the characteristics of needle EMG 
signals allowing them to be used to help diagnose treat and manage neuromuscular disorders. 
Currently, physicians interpret the findings of needle EMG examinations qualitatively, and are often 
prone to bias. There is some reliance on quantitative methods; however these methods are somewhat 
rudimentary. For instance, formal quantization was introduced by Buchthal in the late 1950's, wherein 
normative limits of common MUP features were established. Since then many further attempts have 
been made to establish predictive values and normative limits for specific muscle groups, as seen in 
the works of Podnar (Podnar and Vodusek, 2001; Podnar and Mrkaic, 2002; Podnar, 2009b; Podnar, 
2009a; Podnar, 2004b). Quantitative analysis is able to provide better accuracy of disease detection in 
a way that is more reliable and objective, but suffer other limitations. In particular, the vast amounts 
of numeric data are difficult to interpret, creating many challenges in explaining and presenting such 
findings in a concrete way. 
2.2.1 Conventional Needle Examination 
Current clinical practice is to qualitatively interpret the findings of needle EMG examinations to infer 
the presence or absence, as well as the type of a neuromuscular disorder. Although subjective, a 
qualitative assessment allows an experienced physician to infer a host of underlying conditions and 
diseases by assessing insertional, spontaneous and voluntary needle EMG activity. While lacking the 
precision of quantitative analysis, qualitatively extracted information can provide evidence related to 
disease categories, as well as specific disease processes. 
During a conventional needle EMG examination (Daube and Rubin, 2009), a needle electrode 
(monopolar or concentric) is inserted into the superficial layers of a muscle and the resultant detected 
EMG signals are assessed based on three types of recorded activity: insertional, spontaneous, and 
voluntary. In all cases, the electrode must be positioned to sample several regions of the muscle to 
obtain a sufficient statistical sampling of the MUs. When assessing voluntary activity, EMG signals 
are assessed at a low level of contraction with only a few active motor units contributing to the signal.  
However, if decomposition techniques are used EMG signals with 5-7 MU contributions can be 
assessed.  Either way, it is important to position the needle to detect MUPs with a rapid rise time to 
ensure that the detection surface is sufficiently close to the fibers of the active MUs.  It is also 
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important to ensure that the level of each contraction is consistent, so that abnormally large or small 
MUPs may be attributed to morphological changes in the muscle and thus representative of disease 
and not be related to different sizes of active MUs due to differing levels of muscle activation. QEMG 
techniques have not as of yet been applied to study EMG signals related to insertional or spontaneous 
muscle activity.  As such the following will focus on EMG signals detected during voluntary muscle 
activity. 
2.2.2 Qualitative Characterization 
Traditionally, needle EMG signals detected during voluntary activation are qualitatively characterized 
based on a visual and auditory assessment of the morphology, stability, and times of occurrence of 
their MUPs.  In addition, the intensity of composite EMG signals or interference patterns are 
described using terms ranging from full to sparse in an effort to assess MU activation.  These 
characterizations are usually manually quantized and charted.  While such qualitative assessment is 
prone to a high error rate, a skilled practitioner can use it to detect not just the broad category of 
disease, but also certain processes that are symptomatic of a specific disease or group of disease 
processes. 
MUP analysis is useful in determining the type of disorder, (myopathic or neurogenic) as well as 
the time course and severity of the disease.  However, qualitative analysis is limited to the MUPs of 
only a few active MUs at a time.  MU morphology is inferred based on assessment of the duration, 
amplitude and number of phases of detected MUPs.  Duration is related to the number of MU fibers 
and the size of the MU territory.  Amplitude reflects the contribution of fibers that are nearest to the 
electrode, and can provide an indication of the number and diameter of MU fibers. Amplitude and 
duration typically increases in neurogenic disease and decreases in myopathy.  The number of phases 
refers to the number of baseline crossings of a MUP.  It is a non-specific measure of complexity that 
is related to the synchrony of muscle fiber activity and can indicate the presence of a neurogenic or 
myopathic disorder.  MUP stability refers to consistency of MUP morphology across the MUPs of a 
MUPT. Unstable MUPs are a sign of impaired transmission across the neuromuscular junctions 
(NMJs) of a MU. Although MUP instability is typically a sign of a disease of the NMJ, such as 
myasthenia gravis, any disorder associated with denervation/reinnervation may cause unstable MUPs. 
During qualitative assessment, a physician keeps track of abnormally small or large MUPs and 
polyphasic MUPs and assigns rankings based on their severity and frequency. Once a sufficient 
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number of samples are obtained, the physician forms a subjective impression of the underlying 
disease process based on the evidence obtained. 
MU activation patterns are assessed in terms of the level of MU activation and recruitment. Low 
activation represents a central process such as a CNS disorder or manifestation of pain. Compromised 
MU recruitment is found in neurogenic diseases, and sometimes in end-stage myopathy, whereas 
early recruitment (i.e., increased activation) is typically a sign of myopathy.  According to Shapiro et 
al. (Preston and Shapiro, 2002), MU activation analysis is one of the most difficult tasks for an 
electromyographer. Qualitative MU activation analysis is limited to very low levels of contraction 
where only a small number of MUs are active.  Once a sufficient number of MUs are recruited, the 
overlap of MUPs produces an interference pattern and MU activation becomes qualitatively 
indiscernible. Daube (Daube and Rubin, 2009) and Shapiro (Preston and Shapiro, 2002) describe the 
normal and abnormal variations of MU activation characteristics, and provide further references to 
standardized values for manual visual and auditory assessment. 
2.2.3 Quantitative Electromyography 
QEMG techniques attempt to reproducibly extract useful muscle information from sets of features 
values used to represent important EMG signal characteristics.  Features can represent characteristics 
of a composite EMG signal (i.e., interference pattern) or, of individual motor unit potential trains 
(MUPTs) extracted from a composite EMG signal using either simple triggering techniques or more 
sophisticated decomposition techniques.  With respect to the latter, time domain features related to 
MUP size, shape and stability or features of transformed or modeled MUP waveforms have been 
used. 
Features Used in Quantitative Analysis 
In general, the most immediate benefit of quantitative analysis is the provision of more precise 
continuous values for features like duration, amplitude and number of phases/turns.  Continuous-
valued features also make it possible to derive relationships among features, such as area, thickness 
and size index (Sonoo, 2002), as well as measures of irregularity, such as the 'irregularity coefficient' 
(Zalewska and Petrusewicz, 2005; Zalewska et al., 2004). With the help of Figure 2.2, the commonly-
used features that describe MUP size, shape and complexity are defined next. 
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Duration (ms): The time between the starting (onset) and end point of a MUP. These points 
are often determined using deviation from the baseline and MUP slope 
criteria.  
Amplitude (uV):  The difference in voltage from the maximal negative to maximal positive 
peak within the duration of a MUP. 
Area (uV.ms):  The summation of the rectified MUP signal within the duration.  
Thickness (ms):  The area-to-amplitude ratio (AAR) ( Podnar, 2009b).  
Size Index:  A logarithmic function of thickness and amplitude that is related to the size 
and shape of a MUP (Sonoo, 2002). 
Number of Phases:  A phase is the part of a MUP that falls between baseline crossings and 
exceeds a minimal amplitude threshold. The number of phases is counted 
within the duration. 
Number of Turns:  A turn is a local peak, either negative or positive in the MUP waveform. 
Peaks generated by noise are excluded by defining a turn as a peak that 




Figure 2.2: Features of a Motor Unit Potential (From Stashuk and Doherty: "Normal Motor Unit 
Action Potential" in Neuromuscular Function and Disease, vol. 1, Brown, Bolton and Aminoff, Eds. 
Philadelphia, PA: Elsevier Science, 2002, pp. 291-310.) 
2.2.4 Quantitative Characterization 
QEMG methods use rigorous statistical and/or probabilistic inference, where feature values from 
EMG signals detected in the muscle under examination (i.e., test EMG signals) are compared with 
respect to distributions of corresponding values obtained from exemplary EMG data. By describing 
the statistical similarities or differences between test values and exemplary data, it is possible to 
characterize EMG signals, or constituent MUP waveforms acquired from a muscle under 
examination.  This allows a clinical decision maker to use, to the fullest, the information present in 
the test EMG signals, and in addition, to leverage information extracted from previously acquired 
(exemplary) signals. Such exemplary data must be acquired and stratified by an expert clinician.  In 
addition, it must be specifically acquired for each muscle or groups of muscles studied, and should be 




QEMG analysis has the advantage of providing greater objectivity and consistency, and is useful 
for equivocal cases to increase the certainty of a diagnosis.  Furthermore, the precision obtained with 
more sophisticated quantitative techniques can provide continuous measures that also relate to the 
level of involvement (LOI) of a disorder (Pino and Stashuk, 2008). Compared to qualitative methods 
QEMG methods can be more robust and reproducible. They can provide analytic confidence (i.e., 
provide measures of uncertainty or error) and have the ability to generalize across sets of EMG 
signals. 
The reproducibility and robustness of EMG data assessment are two important criteria used to 
evaluate QEMG methods.  Being able to discuss the degree to which similar features values can be 
obtained from similar EMG signals, coupled with discussions related to the sources and types of 
confounding error present, makes it possible to consider the entire workflow of obtaining decision-
making data from an EMG signal in terms of reproducibility, robustness, and in general the data 
quality associated with the outcome measures associated with EMG based analysis.  Whether EMG 
data is used for exploration of muscle structure and function or to detect and characterize disease it is 
clear that metrics for the quality of the data are invaluable, and by measuring and improving data 
quality, any inference made based on this data will also be improved.   
Regardless of whether a qualitative or quantitative assessment is used a similar hierarchical process 
is followed. First, in order to account for the large variability in MU size and MUP shape throughout 
a muscle, MUP or/and other signal features are assessed at several needle positions within a muscle. 
The data from these various needle positions are then characterized based on whether they possess 
attributes consistent with certain disease processes. The characterized sampled data are then 
combined to arrive at an overall impression or characterization of the muscle. Finally, a rule or 
heuristic is applied to categorize the muscle based on the characterization measures obtained. 
2.3 Decision Support Systems 
One of the main impediments to the wide-spread acceptance of QEMG techniques is the inherent 
difficulty of presenting vast amounts of quantified data in a way that can be easily interpreted. Human 
decision makers have difficulty to interpreting and mentally comparing numeric information without 
the necessary context or level of explanation. Such shortcomings can be overcome by augmenting 
certain QEMG methods within a clinical decision support framework that transforms the vast 
amounts of quantitative data into clinically useful muscle characterizations. 
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Numerous methods of analyzing and interpreting data to provide decision support have been 
reported in the literature. This is especially the case in medicine where large amounts of disparate 
data are analyzed and amalgamated to make critical and time-sensitive decisions. One of the most 
important aspects of a clinical decision support system is its ability to combine two important (and 
sometimes conflicting) capabilities: the ability to characterize consistently and accurately make a 
prediction, and the ability to explain that prediction in a manner that is easily understood by the 
decision maker. 
Therefore, one of the main criteria used in evaluating a CDSS is transparency. Transparency is 
especially important when dealing with complex data structures, such as multivariate distributions of 
MUP feature values or other statistical parameters. A system that can explain its conclusions in a 
manner that is consistent with, and analogous to, the cognitive processes employed by a human 
decision maker, can thus improve upon the quality and accuracy of the inferences made. Therefore, 
the degree to which the findings and supporting evidence can be presented and explained to support 
the decision making process is an important factor to consider when developing a clinical decision 
support system.  How the findings and supporting evidence are presented and explained to support the 
decision making process is also very important. 
2.3.1 Decision Support in Medicine 
The prevalence of clinical decision support systems in medicine is growing exponentially, and 
systems have been proposed, both in the field of neuromuscular disease, and in diagnostic medicine in 
general.  For example, the MUNIN system (Suojanen et al., 2001) uses Bayesian Networks to infer a 
disease based on findings from clinical tests, examinations and patient reports.  A major limitation of 
this system is that a human medical expert is required to 'train' the system by defining conditional 
probability tables.  A machine that can 'learn' without a great deal of user intervention would be an 
asset. The KANDID system (Fuglsang-Frederiksen et al., 1993) uses logical operators and known 
rules to build a knowledge base.  The system is used by making queries that are answered using 1st 
order logic. 
In the field of medicine in general, decision support systems are being developed at a rapid rate. In 
most cases, data from multiple sources, such as clinical evaluations, imaging, and other medical tests, 
are used to achieve a more robust inference.  For example, miniTUBA (Xiang et al., 2007) is a 
medical inference system based on dynamic Bayesian networks (DBN).  DBNs are able to interpret 
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heterogeneous, fluctuating data and are able to capture time varying clinical parameters as well as 
predict the course of disease progression.  While for breast cancer diagnosis (Revett et al., 2005) 
developed a system by combining 'rough sets' and neural networks and (Gevaert et al., 2006) 
developed a breast cancer prediction scheme based on Bayesian networks which combines high-
dimensional microarray data with clinical findings.  In the field of pulmonary diseases, Economou, 
Goumas and Spiropoulos (Economou et al., 1996) initially used ANNs in a decision support system 
and then developed a knowledge base modeled after the methodology used by physicians for clinical 
differential diagnosis to provide decision support (Economou et al., 2001). 
2.3.2 Requirements for CDSS 
Given this widespread use of decision support, attempts have been made to formalize the general 
requirements for clinical decision support in order to guide the development and evaluation of future 
systems.  The works of Konokenko and Sprogar (Kononenko, 2001; Šprogar et al., 2002) and a later 
summary by Pino (Pino, 2009) have generated a list of requirements for clinical decision support 
methods to be clinically useful and safe. These are: 
Transparency: The system must be able to intuitively explain the mechanisms of inference, 
findings, and supporting evidence; 
Accuracy:  Performance of the system must be superior to conventional methods;  
Confidence: A measure of confidence or certainty in the inference or assertion made by 
the system must be provided. Alternatively, the system should fail gracefully 
when a decision cannot be made with certainty, as opposed to reporting an 
incorrect result with high confidence; 
Numeric Value: It is desirable to have a numeric or continuous characterization value or 
measure to facilitate comparisons and longitudinal studies;  
Mixed-Mode Data: The system should be able to handle all types of input data, including 
continuous, discrete, and categorical data; 
Multivariate: Multiple inputs or features must be considered simultaneously so that higher 
order relationships and patterns can be observed; 
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Generalization: The system must be able to make accurate predictions/decisions when 
presented with novel input patterns; 
Missing Data: While missing input values may or may not affect the confidence in a 
decision, it must not compromise the system’s ability to function.  
In addition to these requirements, it is desirable to have a reasoning strategy and flow of information 
that, even in an abstract way, is analogous to the cognitive processes and data assimilation strategies 
employed by a human decision maker.  This helps to establish trust in the system, and provides a 
'consultative' approach, rather than a simple statement of the facts.  
2.3.3 Decision Theory and Evidence Aggregation 
Most decision support systems have a similar hierarchy or structure. At the lowest level, large 
amounts of data (usually numeric) are extracted from one or more clinical test or procedure. These 
data are then combined to support a particular action or decision. The evidence can come from 
disparate clinical tests, as is the case in (Xie et al., 2005), where the results from each test can have a 
different form and must be combined using a data fusion approach. Alternatively, the evidence can 
represent a single test repeated multiple times, as is the case with QEMG examinations, where a 
statistical sampling of MUP morphology is obtained from various needle positions throughout the 
muscle. 
The reliability and diagnostic yield of this data can often vary among tests, as well as within a 
particular procedure. Thus the aggregation step plays a critical role in formulating an overall decision. 
As such, when discussing the transparency of decision support, it is important to consider both the 
transparency of the underlying classifier as well as how the information is structured to support the 
decision making process. Essentially, the flow of information from low-level evidence to high-level 
actions or suggestions must be presented to the clinician in an intuitive way. 
The hierarchical muscle characterization process described previously follows this model quite 
closely. Each MUP characterization is essentially a piece of evidence, provided in the form of a 
conditional probability vector. Each piece of evidence is then aggregated by the CDSS in order to 
make an overall decision about the muscle. By forming a decision in this way, it is possible to 'drill 
down' into each piece of evidence, to determine how it was characterized as well as how it was 
factored into the outcome (e.g., how significantly it was weighted or whether it was a source of 
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confusion). The similarity between this model and the cognitive decision making process employed 
during qualitative interpretation of needle EMG findings provides an effective way to distil and 
communicate the findings of quantitative analysis. 
2.3.3.1 Decision Theory 
The strategies employed in arriving at a decision depend on the amount and quality of evidence 
available. Decision makers often follow two main paradigms when evaluating information, depending 
on the quality or confidence in each piece of evidence. The theories of decision making and analysis 
thus play a crucial role in formulating the aggregation stage of a CDSS, and different strategies can be 
employed depending on the objectives of the decision being made. Such objectives might be to 
maximize characterization accuracy, balance trade-offs between different types of errors (type I vs. 
type II errors) (Duda et al., 2000), or to obtain accurate estimates of decision confidence. A brief 
discussion of relevant aspects of decision theory is thus required. 
Decision analysis is the process of structuring and decomposing hard decision problems into their 
key components and identifying the best option through a systematic approach (Budescu and Yu, 
2006; Clemen and Reilly, 2000). A common situation arises in decision making where the decision 
maker has access to multiple estimates of the probability of an important target event, which need to 
be combined into a single estimate of the certainty in the resulting decision. There are several reasons 
why a decision maker would want to combine multiple sources of information, namely to maximize 
the amount of information that the decision is based on, reduce the influence of extreme sources (i.e., 
outliers), and to reduce the effect of unreliable or inaccurate information (Budescu and Yu, 2006). 
Several studies have shown that combining such pieces of evidence greatly improves the quality of 
prediction of QEMG techniques, and in general (Pino et al., 2009; Pfeiffer and Kunze, 1995; Pfeiffer, 
1999; Hamilton-Wright et al., 2010; Hamilton-Wright and Stashuk, 2006). 
Decision making strategies can be based on two classes of models, namely simple averaging and 
Bayesian (naïve) analysis. While both models have similar accuracy in terms of making the correct 
decision, their underlying principles are different leading to radically different estimates in the 
confidence in a decision. For instance, the averaging model weights each piece of evidence as an 
inverse function of the total number of items, reducing the effect of each piece of information as more 
evidence is made available. In contrast, the naïve Bayes’ model promotes an additive effect where 
each piece of evidence contributes to the decision without accounting for the total amount of 
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information. Essentially, the averaging rule produces a compromise effect while the naïve Bayes’ rule 
produces an extremeness effect (Budescu and Yu, 2006). 
As mentioned, an important aspect of decision making is the confidence in the decision being 
made. Budescu states that the most important predictors of confidence are the level of agreement or 
disagreement between the pieces of evidence, the estimated predictability or likelihood of an event, 
and the total amount of information available. Based on these predictors, it is possible to develop 
aggregation techniques that are a compromise between the two extreme models of averaging and 
Bayesian aggregation. Budescu develops two such models, the weighted mean log-odds (WMLO) 
and the Adjusted Bayes (AB) rule. The WMLO rule is based on averaging, but accentuates the 
differences for extreme values, stretching them out prior to averaging. The Adjusted Bayes rule has 
the effect of pulling in extreme values prior to applying Bayes' rule. Since these measures capture the 
important aspects of both extremes of reasoning, it is expected that they will perform better on 





Muscle Characterization and Clinical Decision Support 
Given the wide variability of MUPs detected in a muscle dependent on the specific needle positions 
during signal detection and the varying degrees to which a disorder may affect specific MUs, 
individual MUP characterization scores are not robust indicators of the actual category or state of a 
muscle (i.e., myopathic, normal or neurogenic) and cannot be used in isolation for accurate diagnosis. 
A more robust indicator can be achieved if several MUP characterizations across a muscle are 
aggregated.  During qualitative analysis a clinician also aggregates, based on experience and training, 
the information extracted from the MUPs and interference patterns examined to create an overall 
clinical impression of the muscle under examination.  Unfortunately, the consistency and accuracy of 
the clinical impression obtained is dependent on the experience of the clinician. However the decision 
support structure and evidence aggregation methodologies presented in the previous section are 
conducive to quantitative muscle characterization based on a statistical sampling of MUP 
characterizations. 
Muscle characterization for decision support is accomplished in two major ways, with varying 
degrees of success in meeting the requirements laid out previously. The simpler and more commonly 
used method relies on statistical analysis of average MUP feature values relative to exemplary data. 
Formal standards and criteria have been laid out to guide this process, and basic decision support can 
be provided through the reporting of such statistics. Inference based on statistical data is commonly 
achieved by applying rules or heuristics to certain statistical properties, or may be entirely left up to 
the clinician. Probabilistic muscle characterization, on the other hand, provides a more transparent 
and intuitive way to aggregate MUP characterizations, forming an overall muscle characterization. 
This method is able to numerically quantify the degree to which a disease is present, along with a 
measure of confidence in its estimate, and is based on a multivariate feature analysis. 
3.1 Statistical Muscle Characterization 
The most common method to address the shortcomings of subjective qualitative interpretation is to 
use summary statistics of quantified MUP features. Statistical techniques go beyond simply 
summarizing quantitative data, and attempt to characterize a muscle based on the distributions of their 
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sampled MUP parameters.  Such predictive analysis techniques form the basis of the early decision 
support techniques. 
Common practice has been to calculate mean values for morphological MUP features, such as 
duration, amplitude and number of phases across sets of MUPs and compare them to normative 
standards reported in the literature to get a muscle-level impression of the state of disease 
involvement.  For example, the early works of Buchthal (Buchthal et al., 1954) are still used as 
standards for formal quantization, and Podnar (Podnar, 2009a; Podnar, 2009b; Podnar and Mrkaic, 
2002) has published predictive values for limb, genioglossus, and anal sphincter muscles.  
Researchers have cited constraints on the minimum number of MUs sampled in a muscle (i.e. the 
preferred number of MUPs sampled for robust diagnosis) and the general consensus is that a 
minimum of 20 MUPs should be sampled (Podnar and Mrkaić, 2003).  However, Podnar showed that 
sampling additional MUPs can increase sensitivity and specificity (Podnar, 2004a).  The major 
drawback with the statistical methods is that for each MUP feature suitable threshold values for 
defining normality/abnormality must be established as well as rules regarding the number of 
abnormal features required to declare a muscle as abnormal. 
To implement a statistical method, a training data set consisting of exemplary 'normal' MUPs is 
used to generate distributions for each feature.  Mean (Stewart et al., 1989) and/or outlier (Stålberg et 
al., 1991) threshold values can then be defined, and feature values of a muscle under test are 
classified based on their locations relative to these limits. For example, Stalberg used a mean 
normative range of +/- 2 standard deviations and considered three different outlier criteria: 95% 
confidence limits; 95% confidence limits for the third highest and third smallest values; and extreme 
upper and lower outlier limits.  No appreciable difference was found across these methods.  A further 
strategy based on this approach applies rules and heuristics to interpret the numbers of outliers and 
deviations from normal mean limits (Pino et al., 2008; Pino et al., 2010; Pino and Stashuk, 2008).  
Several works by Podnar (Podnar, 2004b; Podnar, 2005; Podnar, 2008) have performed comparisons 
of different outlier criteria and have established standardized normative limits for diagnostic criteria. 
The intention of QEMG analysis is to increase both sensitivity (number of correct positive 
decisions) and specificity (number of correct negative decisions).  For every decision, the objective is 
to maximize sensitivity and specificity. However, sensitivity and specificity cannot be simultaneously 
maximized and often involve some amount of trade-off or compromise.  Therefore, with regard to the 
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decision making process, whether it is better to be less specific in order to be more sensitive must first 
be made.  Best practice is to determine the minimum number of overall errors by balancing sensitivity 
and specificity unless the cost of poor sensitivity relative to specificity or vice versa can be 
determined.  In this regard, statistical muscle characterization methods have two main implementation 
issues: First, it is difficult to suitably define thresholds of normality/abnormality.  Second, much 
confusion exists in determining suitable categorization rules.  For instance, a rule might state that a 
minimum number of outliers must be present to declare abnormality, but results may vary depending 
on which features happen to have outliers.  On the other hand, a single feature might have sufficient 
evidence due to the number of outlying MUPs.  Such a feature may or may not fail the 'mean' test 
depending on the distribution of its MUP feature values but based on outlier criteria clearly 
demonstrate abnormality. 
3.2 Probabilistic Muscle Characterization 
Statistical muscle characterizations have two main weaknesses in addition to the implementation 
issues cited above: 1) they are unable to provide a measure of, the quality of, or confidence in, a 
particular inference, and 2) they use thresholds defined using averages and deviations across sets of 
MUPs (20 or more) making it difficult to investigate the rationale for a particular result at the level of 
the individual MUPs.  Both of these weaknesses reduce the transparency of decisions made.  A 
probabilistic approach addresses these weaknesses by providing information at the muscle level as 
well as the MUP level, thus allowing for the provision of a detailed explanation of the underlying 
decision-making process. The term 'characterization' in this sense takes on a more complex definition, 
but with the same end result as described for statistical characterization. A probabilistic 
characterization is one that assigns a score or likelihood measure to each muscle category under 
consideration.  Ideally the score represents the probability of the examined muscle being affected by a 
disease of a particular category conditioned by the specific characteristics of the set of its sampled 
MUPs.  A characterization is a set of n scores, where n is number of muscle categories under 
consideration (typically 2 or 3). 
The probabilistic muscle characterization (PMC) framework was first introduced by Pfieffer 
(Pfeiffer and Kunze, 1995; Pfeiffer, 1999) and further developed by Pino and Hamilton-Wright (Pino, 
2009; Pino et al., 2010; Hamilton-Wright and Stashuk, 2006; Pino et al., 2008; Hamilton-Wright et 
al., 2010). Many studies have shown it to be superior to both statistical muscle characterizations as 
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well as conventional subjective examinations (Pfeiffer and Kunze, 1995; Pfeiffer, 1999; Stewart et al., 
1989; Stålberg et al., 1991; Podnar, 2004b; Podnar, 2005; Katsis et al., 2007; Pino et al., 2008; Pino et 
al., 2010). The PMC framework relies on a knowledge base of exemplary training data collected from 
patients with known pathology and healthy controls (see Figure 3.1). The characterization of a muscle 
under test then follows a process that is similar to a conventional needle EMG assessment of MUP 
morphology. MUPs are sampled uniformly at points throughout the muscle to obtain a statistical 
representation. The detected EMG is then decomposed into its constituent MUPs using 
decomposition techniques described elsewhere (Stashuk, 1999; Stashuk, 2001). The MUPTs are then 
individually characterized in terms of the exemplary data based on morphological features of MUP 
shape, size and complexity. The individual MUPT characterizations are then combined into a muscle 
characterization using a suitable aggregation scheme (see Figure 3.2). A heuristic is then applied to a 
muscle characterization in order to infer a particular category of disease. In most cases, the standard 
rule is to select the category with the highest characterization score as the winner. Based on the 
muscle characterization, a numerical measure of the confidence in the predicted outcome is also 
calculated. The level of involvement can be obtained in a similar fashion; however appropriate 
aggregation schemes and techniques have not yet been assessed. One of the goals of this work is to 
determine if and how the type of aggregation method used affects the way in which characterization 
scores are calculated, and whether various strategies of compromise or extremism may be more suited 
to a specific goal. Thus, optimal strategies to maximize accuracy in detecting disease while balancing 









Figure 3.2: Aggregation of MUP scores into a muscle characterization 
3.2.1 MUP Characterization 
Based on a training set of features extracted from exemplary MUP templates, a MUP characterization 
consists of a set of scores that indicate the likelihood that the muscle from which a MUP template was 
calculated is affected by a specific category of disease based on the characteristics of the MUP 
template.  In a two-category case, the likelihood of a muscle being normal or abnormal conditioned 
on the characteristics of the MUP template is estimated, or in a three category case, which is more 
common, the likelihood of a muscle being normal, myopathic or neurogenic conditioned on the 
characteristics of the MUP template is estimated. Alternate class stratification may also be used, as is 
the case when working with data that represents different levels of involvement, but require training 
data to be specifically acquired and stratified by an expert.  
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MUP characterization can be performed using a variety of pattern recognition techniques. Many of 
the conventional continuous classifiers based on probability theory perform reasonable well; while 
more advanced techniques have the potential to improve upon one or more of the CDSS requirements 
laid out previously. 
Conventional Classifiers 
Several MUP characterization techniques that are based on classifiers that use continuous valued 
features have been considered in the literature. The most common of these is linear discriminant 
analysis (LDA) (Duda et al., 2000), and was used by Pfeiffer and Kunze, and later by Pino, Stashuk, 
and Podnar as a candidate for a muscle characterization methodology (Pfeiffer and Kunze, 1995; 
Pfeiffer, 1999; Pino, 2009; Pino, et al. 2010; Pino et al., 2008). 
LDA statistically transforms data in an attempt to minimize within-class scatter (variance) while 
simultaneously maximizing between-class scatter to achieve an optimal decision function for each 
muscle category.  Pino and Stashuk (Pino et al., 2008) evaluated the performance of LDA, decision 
trees (DTs) and a standard Naive Bayes (NB) classifier (Duda et al., 2000), and found that MUP 
categorization performance was comparable across these methods.  The advantage of conventional 
classifier techniques is that their simplistic nature allows for some degree of transparency, provided 
that a clinician has a moderate statistical background, although their performance is subject to the 
data upholding certain assumptions such as obeying a Gaussian distribution and independence across 
features. 
Advanced Pattern Recognition Techniques 
When MUP categorization accuracy is considered as the evaluation criteria, conventional 
classification techniques do not provide the best performance.  Therefore advanced pattern 
recognition techniques have been used to improve performance.  In these studies, the true categories 
of MUP templates were manually determined by an expert neurophysiologist to create a MUP 
database. In their early works, Pattichis (Schizas et al., 1999; Pattichis, 1999) was the first to develop 
a decision making strategy based on artificial neural networks (ANNs) combined with Kohonen self-
organizing feature maps (SOFM) and a learning  vector quantization (LVQ) technique to perform 
MUP characterization based on morphological MUP features.  Katsis (Katsis et al., 2007) used ANNs 
with radial basis functions and probabilistic neural networks (PNNs) in a two-stage classification 
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approach. The first stage used an ANN or PNN to discriminate between normal and abnormal MUPs, 
and the second stage used a C4.5 decision tree (Salzberg, 1994) to determine whether the abnormality 
was myopathic or neurogenic. Although these advanced pattern recognition based MUP 
characterization techniques are robust and accurate, several drawbacks have been noted.  For 
example, ANN methods have a tendency toward over-fitting resulting in a difficulty to generalize to 
new data. In addition, while most of the advanced pattern recognition techniques, including ANNs, 
SVMs and others, offer greater sensitivity and specificity they do not provide good transparency.  It is 
difficult to intuitively appreciate how they make their decisions.  Poor transparency leads to poor 
acceptance of results by clinicians. 
Transparent Rule-based Techniques 
The need for transparency can be addressed by employing rule-based methods.  The two-stage 
method developed by Katsis is able to provide a level of partial transparency and interpretability by 
using a decision tree to discriminate between myopathic and neurogenic categories.  However, the 
most promising techniques involve the use of pattern discovery (PD), developed by Wang and Wong 
(Wong and Wang, 1997).  Pino (Pino, 2009; Pino et al., 2008) demonstrated that PD had comparable 
performance to the continuous classifier methods while meeting the necessary conditions for clinical 
decision support. 
PD quantizes all feature values into events.  In a training set, patterns of events across the features 
used to represent a MUP and including a specific muscle category, which occur more often than 
expected under the assumption of independent features and categories, are selected by PD as rules.  
The entire set of discovered rules form a knowledge base that can be used for categorization of test 
MUPs.  If a pattern of events created by the quantized feature values of a test MUP match a rule 
associated to a pattern discovered in the training data that occurred more often than expected it is used 
as positive evidence and supports the category contained in the rule.  Alternatively, if the matched 
rule is associated to a pattern discovered in the training data that occurred less often than expected it 
is used as negative evidence and refutes the category contained in the rule.  The degree of support or 
refutation is measure by the weight of evidence statistic.  The order of a pattern or rule refers to the 
number of features involved in the rule, including the class label. While PD was been shown to have 
accuracy comparable to other classification techniques, it may not be considered to be as robust as 
some of the other classification methods, due to the need to quantize feature values.  The number of 
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intervals ('bins') used for quantization must be carefully selected to manage the trade-off between the 
level of granularity (and accuracy), and the quality of evidence.  For example, if the number of 
intervals increases, more training data is needed to determine if specific patterns are significant.  
Decreasing the number of intervals results in larger quantization ranges, which decreases the 
precision of the MUP representation. 
It is also worth discussing a hybrid fuzzy logic-based variant of PD developed by Hamilton-Wright 
(Hamilton-Wright and Stashuk, 2006). In other areas of medicine, fuzzy-logic based inference 
systems offer an attractive alternative to conventional characterization techniques.  The general idea 
is to represent hard numeric values by linguistic expressions, where a membership function 
determines the degree to which a variable falls within a particular decision boundary.  The benefit of 
such a system is that it allows quantities to be represented by linguistic qualifiers like somewhat high, 
high, very high, and expressions such as hot, cold, warm.  Hamilton-Wright proposed a fuzzy 
inference (FI) system that augmented PD with fuzzy logic theory.  Quantization error is greatly 
reduced because values within a bin are assigned memberships based on their position.  The 
'fuzziness' of membership values allows multiple rules with the same feature value to be considered 
simultaneously, selecting the rule that yields the best discrimination.  Information presented in this 
way is also more in line with the way humans interpret and reason with data they are presented with, 
making it an excellent candidate for use in decision support. 
3.2.2 Evaluation of MUP Characterization Techniques 
In order to be clinically useful, a classifier must meet the requirements laid out in section 2.3.2. As 
long as the characterization technique is capable of meeting each of these requirements to a 
satisfactory degree, then transparency can be considered to be the criteria of greatest importance. 
Conventional classifier methods are simplistic enough that they may provide some level of 
transparency to clinicians familiar with the concepts of differential diagnosis.  However, several 
drawbacks of these methods, such as unmet assumptions regarding feature data distributions, can 
limit the accuracy of these methods for MUP categorization.  The advanced pattern recognition 
techniques, such as ANNs and SVMs, are quite robust and offer better performance.  However, ANNs 
are essentially 'black-box' classifiers that do not permit an explanation of their output.  Even if such 
an explanation were possible, it would not be in a form that is easily assimilated by a human decision 
maker.  SVMs also suffer from their complexity and require a deeper appreciation of their theoretical 
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mechanisms. While providing accuracy comparable to the other methods, the PD and the FI 
techniques introduced by Pino and Hamilton-Wright offer a completely transparent classification 
scheme. PD is unique in that it combines information theoretic principles with linguistic 
interpretation.  At the heart of the method lies a robust statistical and probabilistic analysis, but the 
rules derived from patterns in the data are in a form that can be intuitively understood and easily 
displayed.  In addition, PD and FI are capable of handling continuous and discrete feature values as 
well as missing data.  Further, it is believed that the rule-based nature of PD allows it to generalize its 
conclusions to new data better than other classification techniques.  
3.2.3 Muscle Characterization 
Despite the fact that MUPs can be characterized with high accuracy, there is a high degree of 
variability across MUP characterizations, even for MUPs detected in the same normal muscle, 
thereby limiting their diagnostic potential. However, a robust muscle characterization can be obtained 
by aggregating information across a set of MUPs detected from a muscle under test.  An overall 
muscle characterization is achieved by aggregating the characterizations from individual MUPs.  Just 
as in the MUP case, a score is produced for each category under consideration.  The muscle is then 
categorized as being from the class that has the highest conditional probability score. 
Confidence 
A muscle conditional probability can also be thought of as the confidence in a particular 
categorization. While confidence is not directly evaluated in this work, it is necessary to understand 
its basis as it plays a central role in the aggregation of information. A measure of confidence 
(obtained from the highest muscle characterization score) should reflect the probability that the 
muscle from which the MUPs were detected is actually of the given category, conditioned on the 
evidence provided by the set of MUP characterizations.  In this way, a muscle characterization 
measure can be thought of as the confidence in making a particular categorization based on the 
available evidence.  A well calibrated muscle confidence score of 80% for a given category means 
that, out of all the muscles that are assigned that score, 80% are truly of that category (Pino, 2009).  In 
practice, it is therefore useful to calibrate muscle scores to reflect true conditional probabilities, using 
a technique such as Monte Carlo simulation (Pino, 2009) or similar method. 
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Level of Involvement (LOI) 
LOI can be thought of in two ways: continuous and discrete. Continuous LOI, as considered in (Pino 
and Stashuk, 2008), is a single numeric value that is monotonically increasing with respect to the 
severity of disease. Such a measure can be obtained by analyzing the MUP characterization scores, or 
the actual feature values relative to exemplary data. For instance, averaging has been shown to 
produce muscle confidence scores that correlate well with actual LOI, while Bayes’ rule tends to 
saturate to values of 0 or 1 as more evidence is considered. Discrete LOI, on the other hand, is very 
much like disease detection. Training data is stratified based on various discrete levels of disease 
severity, such as low, medium, and high. The MUPs of the muscle under test are then characterized 
with respect to this stratification, and the end result is a characterization vector where the scores 
represent conditional probabilities for each of the LOI strata. Any of the aggregation measures above 
could then be used to predict the confidence in this decision, once a particular category is selected. 
Another principle goal of this work is to determine which of these strategies would be most useful to 
a clinician. 
3.2.4 Aggregation Methods and Decision Making 
The most common aggregation methods considered in the literature include the averaging rule (AR) 
based on the arithmetic mean, and Bayes' Rule (BR), which is consistent with the two main decision 
making strategies discussed earlier. Pfeiffer and Kunze (Pfeiffer and Kunze, 1995; Pfeiffer, 1999) 
first introduced the idea of probabilistic characterization by using Bayes' rule for multiple pieces of 
evidence to aggregate MUPs that were characterized using Fisher's linear discriminant analysis.  Pino 
considered several aggregation metrics, including AR, BR, and the z-transform (Whitlock, 2005). 
Several other techniques have been developed to aggregate evidence, and are applicable to this 
framework. For instance, Budescu (Budescu and Yu, 2006) developed and evaluated two separate 
techniques that attempt to achieve a compromise between Bayes' and averaging. Since the muscle 
characterization scores generated using BR tend to saturate to 0 or 1 as more evidence (higher number 
of diseased MUPs) is presented, a rule that is less prone to saturation, while still taking into account 
the significance of outlier data, is desired. 
The rules developed in (Budescu and Yu, 2006) are believed to reflect a decision maker’s 
judgments more accurately on average. In reality, a decision maker’s judgment is greatly influenced 
by the quality and amount of evidence, as discussed previously. However, the strategies employed are 
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prone to bias and the quality of evidence is not generally known in advance. The two compromising 
methods will hopefully retain the desired qualities of AR and BR: when the evidence is suspect or 
weak, the conservative effects will consider all of the evidence equally, and when outliers are present 
in more than one category, they will be discounted rather than being allowed to saturate the decision 
towards the wrong category. It is expected that the average accuracy of these methods will fall within 
the range of accuracy of the AR and BR methods. In fact, the ordering, from most conservative to 
most extreme is expected to be AR, WMLO, AB, and finally BR.  WMLO and AB are expected to 
have a better balance across classes that are easy or difficult to classify, whereas BR will perform 
better for well-separated classes and AR will perform better for more challenging class separations. 
The aggregation measures considered for decision-making in this work are presented next: 
Average Rule (AR) 
The simplest aggregation method is to use the arithmetic mean. The AR characterization measure is 
calculated separately for each category by taking the arithmetic mean of the set of MUP 
characterization scores per category. Averaging is considered to be conservative because each piece 
of evidence is inversely weighted by the total amount of evidence. Thus, as more evidence is gathered 
(in this case MUPs), each MUP characterization is weighted less significantly, reducing the pull of 
any one particular outlying value. The equation for AR is given as 
                            
 
 
         
 
   
                
Where for equations 3.1 through 3.6, 
yk   represents the muscle category (i.e., normal, myopathic, neurogenic), 
P(MUPi | yk) is the probability of MUPi conditioned on having come from category yk (i.e. 
the MUP characterization score assigned to category yk), 
N   is the number of MUPs detected from the muscle under test, and 
K   is the number of muscle categories used for classification. 
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Bayes Rule (BR) 
Historically, Bayes has been shown to have better performance in muscle characterization. Typically, 
when detecting disease, the most significant information is contained in the presence of outliers. This 
follows from the more conventional techniques such as statistical analysis or even subjective analysis: 
when more diseased MUPs are present than expected, the clinician often concludes that the muscle is 
diseased. Thus, BR is additive2 in that each piece of evidence adds to the total evidence supporting a 
particular category, and stronger pieces of evidence carry more weight. The equation for BR is given 
as follows: 
                                     
 
   
                 
 
   
 
 
   
 
  
             
Weighted Mean Log-Odds (WMLO) 
The weighted mean log-odds method is essentially an averaging rule. However by considering log-
odds prior to averaging, the differences for extreme (low or high) probabilities are accentuated. In this 
way, evidence that is thought to contain more significant information is given a higher weighting. The 
equation for WMLO is provided here, however a derivation based on log-odds is provided in 
Appendix A. 
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Adjusted Bayes (AB) 
The adjusted Bayes rule is a modified version of BR that includes an adjustment factor. The 
adjustment factor makes it possible to discount the impact of extreme evidence, essentially pulling in 
                                                    
2
 To visually appreciate the additive nature of BR, the equation must be expressed in terms of logits. See 
Appendix A for an explanation and derivation. 
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extreme probabilities prior to the application of Bayes rule. A scale-factor of one results in the naïve 
Bayes rule.  
                                          
 
   
                   
 
   
 
 
   
 
  
       
And 
                                
                  
 
 
   
 
  
       
Where 
λ is the risk adjustment parameter that controls the level of discounting of extreme 
sources of information (Budescu and Yu, 2006). Note: a value of 0.5 was used for all 
calculations in this thesis. 
3.2.5 Data Stratification for Confidence and LOI 
As a starting point for most QEMG methods, especially those augmented with a CDSS framework, 
the common approach is to discriminate between broad disease categories such as neurogenic or 
myopathic, or even the simpler dichotomous states of 'normal' and 'abnormal'. To date, studies 
suggest that suitable performance can be obtained at this level of decision making, and these methods 
have been shown superior to conventional methods (Pino, 2009; Pino et al., 2010; Pino et al., 2008). 
The main goal of this work then, is to expand the granularity or resolution of reported clinical states 
in an effort to provide more information to the clinician, specifically the level of involvement of a 
disorder. Obtaining such additional information however, should not compromise accuracy or quality 
of performance. 
The idea of confidence also applies to single MUP characterizations, since these are also 
conditional probabilities. At this level, the measure of confidence is affected by the amount and 
quality of the training data. Feature values that fall close to the ‘centroid’ of a particular set of 
exemplary data will have higher MUP confidence scores. Such highly confident MUP 
characterizations can be thought of as outliers or strong pieces of evidence in support of a particular 
category. Conversely, MUPs with feature values that do not clearly belong to a particular class will be 
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reflected by lower confidence scores, and their characterization vectors will likely show confusion 
across categories. An important requirement then, is to have accurate estimates of conditional 
probabilities. 
One approach to attempt to improve conditional probability estimates is to further stratify the 
training data by discrete levels of involvement, rather than by having a wide range of feature values 
represented by a single broad category. In training data comprised of differing degrees of disease 
progression, the overlap of distributions may lead to higher errors, particularly in cases where feature 
values lie close to the normal/disease class boundaries (as with low LOI). By representing the 
individual LOI states more concisely, more subtle morphological MUP changes can be detected, 
leading to better discrimination, and higher levels of confidence in predicting specific LOI categories. 
However, by increasing the stratification of training data, more data will be needed to represent each 
class. Also, since there is considerable overlap between the distributions of different LOI categories, 
performance would be expected to drop regardless of the training set size. 
This work introduces a hybrid classification approach that utilizes the advantages of more compact 
data distributions to increase sensitivity and specificity of disease detection. Off-by-one classification 
errors are then combined, in order to report the higher level clinical state with greater accuracy and/or 
confidence. To illustrate the concept, consider a case where a muscle characterization was produced 
that was divided between myopathic and neurogenic (i.e., had strong support for both disease 
categories) would still be of clinical utility because it would provide strong evidence for disease 
versus normality if the evidence was combined. In such a case, confidence for each disease category 
might be low, but confidence in the presence of disease would still be high. If the clinical goal was to 
simply detect abnormality, then greater accuracy would be obtained in this case because the classifier 
had knowledge of the specific disease states. Thus the reference point used in measuring accuracy and 
confidence play a significant role. 
Similarly, estimates of the level of involvement of a disorder would also vary with respect to the 
chosen reference, and would depend on the class hierarchy or stratification being reported. For 
instance, if training data were stratified into levels of involvement (e.g., 25%, 50%, 75% or possible, 
probable, definite), there would be much confusion between these sub-strata due to distribution 
overlap, but the general detection rate of the underlying disease might be improved by providing 
examples of specific ranges of abnormality within each class. One goal of this work is to determine a 
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compromise between category resolution (i.e., the number of clinical LOI states reported) and the 
accuracy with which each state is detected. A reasonable trade-off of category resolution and 





Data Used for Evaluation and Clinical Validation 
Simulated EMG data was used to develop and test the PMC framework. The results were then 
validated by repeating a subset of the tests on real world data. This section first describes the data sets 
used, and then discusses descriptive statistics and presents feature distributions that may give an 
indication as to the ease or difficulty with which the data can be classified. 
4.1 Data used for Evaluation 
To form a basis for discussion in evaluating the classification and aggregation techniques at different 
degrees of disease progression (i.e., levels of involvement), EMG data was simulated according to an 
electrophysiological model (Stashuk, 1993). The simulator was used to create pools of data that are 
representative of the main categories of neuromuscular disease (i.e., healthy, myopathic and 
neurogenic). To simulate a neuropathy, motor units are randomly atrophied, while orphaned muscle 
fibers are randomly re-innervated by nearby surviving motor neurons that are within a defined range. 
To simulate myopathy, a percentage of healthy fibers are 'infected' in a manner where some fibers are 
atrophied (in diameter) to a small degree while others are hypertrophied to an even smaller degree. 
This process is iterated to successively infect fibers to a larger degree, while at the same time 
infecting new fibers, until a prescribed level of involvement is reached. A fiber is considered non-
functioning (i.e., dead) when its diameter is below a critical threshold. Muscle activation is regulated 
by specifying the percentage of maximal voluntary contraction (MVC) force generated in a healthy 
muscle. If a disease process is present, the number of motor units recruited and their firing patterns 
are either increased or decreased, to achieve the same level of force. 
The simulated muscle signals were modeled to have been detected using a concentric needle 
electrode that sampled the muscle at various intramuscular locations within a 2mm square centered 
about the muscle model's center. All contractions were acquired at 10% MVC and were decomposed 
into constituent MUP trains using DQEMG (Stashuk, 2001) software. 
When stratified by disease category, the myopathic and neurogenic MUP pools were comprised of 
about 1000 MUPs each. The control MUP pool had a total of 1500 MUPs. The stratification of MUPs 
into disease categories (CTRL, MYO, and NEUR) represented the lowest resolution of classification 
available. The myopathic and neurogenic MUPs were simulated to come from muscles with 25%, 
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50% and 75% muscle-fiber/motor-unit loss, in approximately equal proportion (approximately 300 
MUPs in each LOI pool). Each pool of diseased MUPs was further stratified by LOI (labeled MYO-
25, MYO-50, MYO-75, NEUR-25, NEUR-50, and NEUR-75). This stratification represented the 
highest resolution of classification available, with the CTRL group included as the seventh class. 
4.2 Data Used for Validation 
Data was obtained from a clinical source in order to validate the findings that were evaluated using 
the abovementioned simulated data. However, the dataset represents only a single disease state 
(myopathic), and is stratified into two levels of involvement rather than three. This poses several 
limitations in applying the methods developed in this work. 
4.2.1 Muscular Dystrophy Data (MDX) 
Disease and control data collected at the London Health Sciences Centre (London, Ontario) 
comprised of several types of muscular dystrophy at various levels of severity, as well as a set of 
control subjects. In total, there were four patients with facioscapulohumeral dystrophy (FSHD), six 
patients with limb-girdle muscular dystrophy (LGMD), and five patients with Becker's muscular 
dystrophy. The control group consisted of seven subjects. 
The study was comprised of fifteen individuals, with a previously determined diagnosis of 
muscular dystrophy, and a group of seven healthy subjects with no evidence of neuromuscular or 
musculoskeletal disorders. Participants diagnosed with muscular dystrophy were recruited through the 
Neuromuscular Clinic at University Hospital, London Health Sciences Centre, London, Ontario. 
Diagnosis was confirmed by clinical assessment and genetic testing. Control subjects consisted of 
recreationally active individuals recruited from the university environment. 
Among other aspects of the protocol, each patient's maximum voluntary contraction (MVC) of the 
quadriceps muscle was recorded via a torque gauge and oscilloscope. Needle EMG was recorded 
from the biceps, vastus lateralis, and tibialis anterior muscles of each patient. Patients from the 
disease group were arbitrarily divided into equal groups of low and high levels of severity based on 
their quadriceps MVC measures. 
The lowest resolution of classification was obtained when MUPs were stratified by disease, 
resulting in two categories or clinical states (CTRL, MYO). The MYO pool was further stratified by 
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LOI (labeled MYO-L, MYO-H). This stratification represented the highest resolution of classification 
available, with the CTRL group included as the third class. 
4.3 Statistical Analysis of the MDX Data Set 
A preliminary analysis of each of the data sets was conducted in order to gain a qualitative 
appreciation of the underlying distributions of data. Selected feature distributions were plotted using a 
Parzen window estimation technique and Gaussian kernel (Duda et al., 2000)3. The density estimate 
was evaluated at 100 equally spaced points covering the range of the feature data. Feature densities 
are plotted in Figure 4.1 through Figure 4.9 for the control group and for each LOI group on a single 
plot per disease category. 
4.3.1 Analysis of Feature Distributions 
Distribution plots of selected features are presented for discussion. As discussed in the background 
section, certain MUP features, such as phases and turns, are non-specific and increase with 
neuromuscular disease. However, other features, relating to size and shape, have specific trends that 
depend on the underlying disease process. A plot of area density for each level of severity illustrates 
these trends. In a neurogenic disease process, area increases with LOI and decreases with LOI in a 
myopathic disease process, as illustrated in Figure 4.1 and Figure 4.2. Similar trends are observed for 
thickness and duration in the neurogenic case. The trends seen in myopathic data are validated using 
the MDX data set (refer to Figure 4.3). For the most part, the number of turns and phases either 
increase, or stays relatively the same. 
Two notable exceptions are seen with turns, thickness and duration in the myopathic case, 
particularly with simulated data. First, the distribution of turns is more concentrated around a value of 
three for normal MUPs, and increases with disease (see Figure 4.4 and Figure 4.5). However, it is 
interesting to note that there are fewer MYO-75 muscles with very high turns, suggesting that as LOI 
increases, the likelihood of finding MUPs with higher numbers of turns actually diminishes, and tends 
toward the normal category. This is contrary to the expectation that complexity should grow with 
disease severity.  Thickness also shows an odd trend, and seems to shift to the right (increase) for 
lower levels of myopathy, but as the level of disease increases, the range of thickness values widens 
                                                    
3 The window parameter, u, was calculated using the expression, u = s*(4/(3*N))^(1/5),where s is the 




due to an increase in the likelihood of abnormally thin MUPs (see Figure 4.6 and Figure 4.7). 
Although the initial increase is not expected, a reduction of thickness with myopathy is typical. 
Duration was also found to have an uncharacteristic initial tendency to increase, and then decrease 
with higher LOI as the likelihood of shorter MUPs increases, but not to the degree that would be 
expected (Figure 4.8). Similar trends were not observed in the MDX data (Figure 4.9), except in the 
case of turns where there is a higher likelihood of lower turn values for the severe group. 
 




Figure 4.2: Estimated distribution of area - simulated myopathic data
 




Figure 4.4: Estimated distribution of turns - simulated neurogenic data
 




Figure 4.6: Estimated distribution of thickness - simulated neurogenic data
 




Figure 4.8: Estimated distribution of duration - simulated neurogenic data
 
Figure 4.9: Estimated distribution of duration - simulated myopathic data 
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4.3.2 Statistical Analysis of Clinical Data 
Previous work (Derry, 2010) applied statistical hypothesis testing to the MDX data to determine 
which, if any, of the average MUP features were significantly different across LOI and control 
groups. The findings are summarized in this section. 
4.3.2.1 MDX Data 
Statistical analysis performed by the researchers involved in this study showed significant differences 
between diseased muscle groups and control subjects for MUP amplitude, AAR and turns in one of 
more of the three muscle groups (e.g., VL: p < 0.0001, TA: p < 0.05, BB: p < 0.0001), but no 
significant differences for the average number of phases (Derry, 2010). 
In the vastus lateralis, MUP duration, area, and AAR were significantly different (reduced) in the 
severe group compared with the mild group (p < 0.0001), however no significant differences were 
observed between groups for amplitude, number of phases or turns. For the tibialis anterior, only the 
number of turns was found to be significantly different (p < 0.01), and for the biceps brachii both 
turns and phases were significantly different (p < 0.0001). No significant differences were noted 
between the mild MD and control groups (Derry, 2010). 
4.4 Discussion 
For most of the features discussed, the expected trends are observed in both the simulated data and 
clinical data sets. However, the notable exceptions occurring in simulated myopathic data for turns, 
duration and thickness can suggest several things. In particular, since these trends were not confirmed 
in the MD data set for duration and thickness, there are two possibilities. First, the simulator model of 
myopathy may be inaccurate for low levels of myopathy, in that the ratio of fiber death to fiber 
infection may be too low. Thus for low levels of involvement, a large number of inactive fibers would 
add a significant delay in conduction of the MFP, resulting in abnormally longer durations. A second 
possibility is that the MD data was collected from patients who had higher levels of disease severity. 
As such, any early restructuring that could explain these distribution patterns was no longer present, 
and fiber atrophy was already the predominant effect. In either case, some degree of discrepancy 
between the model for myopathy and the actual disease process is likely present. 
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The distribution of turns suggests that there is simply a higher variance in turns as LOI increases. 
While this is not useful on its own, a classifier such as PD might be able to detect useful patterns such 
as low area and increased or decreased turns. 
Distributions for the remaining muscles of the MD data set were not evaluated. Since the vastus 
lateralis (VL) muscle was used to measure MVC, and it is that MVC measure that was used to stratify 
the data, it is expected that the best separation among classes would be seen in the VL group.  
The distributions presented and discussed show that there clearly are observable changes between 
control and disease groups, and further between various LOI groups. However, conventional 
statistical analysis suggests that the separation between low LOI groups and control groups is not 
significant. Further, when discussing single features, the limitations in predicting the likelihood of a 
particular category based on MUP feature values are quite obvious. It is for these reasons that the 
probabilistic techniques presented in this thesis have a significant advantage. The first advantage 
stems from the fact that these methods employ multivariate statistics, allowing simultaneous 
consideration of several features and increasing the richness of information available. The second 
possible advantage stems from the fact that non-linear trends in feature distributions can lead to 
unique patterns in the data. A classifier such as PD would be able to detect these patterns, and with 
sufficient training samples, should outperform conventional linear classifiers such as LDA. The wide 
ranges of values present in these data also suggest that standard disease-based stratification would 
have some limitations, particularly with lower LOI. LOI-based stratification presents further problems 
because of the amount of overlap between LOI group feature distributions. Thus the hierarchical 
techniques that will be considered in this work will attempt to address these limitations. By 
classifying data with the highest level of granularity or resolution, and then reducing this resolution to 
the desired level, it is possible to capture the subtle changes in MUP morphology that are essential for 
discrimination. This is of most importance for low LOI, because many of the MUP features have 
significant overlap with the control group. If these feature values in this range are not properly 






The previous chapter described current implementations of the PMC framework and identified 
several areas for improvement. Namely, current methods perform reliably when detecting disease in 
muscles with high disease LOI but tend to perform poorly at detecting disease in muscles with low 
LOI. A hierarchical classifier is developed and compared with existing methods with the objective of 
improving the balance of accuracy across LOI groups. To further the utility of quantitative methods, a 
second objective is to provide a clinically useful measure of LOI in the form of clinical LOI states. A 
variation of the hierarchical method is considered to determine the optimal resolution of LOI states 
that can be reported with reasonably high accuracy. Continuous measures of LOI are also considered, 
since previous techniques have demonstrated that although muscles correlate well with LOI, the wide 
range of scores within each LOI group makes it difficult to measure LOI reliably. Techniques are 
developed to attempt to reduce this variability. Finally, to understand the impact of different decision-
making strategies (conservative versus extreme), the behavior of the aggregation measures introduced 
previously is studied as the amount of evidence is varied. In particular, the number of MUPs 
considered in characterizing the muscle is increased at specified intervals. The purpose of the latter 
analysis is to deterministically describe the conditions that affect the performance of each aggregation 
measure, so that appropriate measures can be used to optimize global performance. 
5.1 Clinical States for Diagnosis 
For the simulated data used for evaluation purposes, there were three clinical states on which to base 
a diagnosis, namely normal (CTRL), myopathic (MYO), and neurogenic (NEUR). These states 
represented the highest level of stratification, or the coarsest stratification resolution that was possible 
for classification. Other studies have considered an even more general stratification using only two 
classes (e.g., normal vs. abnormal) (Katsis et al., 2007; Stålberg et al., 1994; Stewart et al., 1989). It is 
possible that such higher level stratification would be desirable from a workflow perspective, but 
would not necessarily lead to improved performance. For each disease category, the data was further 
stratified by simulated level of involvement, resulting in low (L), medium (M) and high (H) LOI 
groups. This represented the lowest level of stratification and subsequently finest level of resolution 
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available for classification. The CTRL group was not sub-divided in such a manner, thus in total there 
were seven high-resolution classes. 
5.1.1 Data Stratification and Terminology 
To provide clarity for the reader, efforts have been made to use consistent terminology wherever 
possible. Perhaps the most confusion lies in explaining the ideas of data stratification. Strictly 
speaking, when discussing how data is stratified for the purposes of classification, individual pools of 
training data are assigned to a particular category using a class label. Thus, these terms may be used 
interchangeably to refer to the class-structure of a training set. The term category is also specifically 
used to refer to particular strata of disease or LOI group, or to describe a clinical state presented to a 
decision maker. Following this logic, a characterization is the set of scores assigned to each category, 
and can be applied to a muscle or an individual MUPT. Although the muscles used for testing are also 
stratified by LOI category, they are referred to as groups (i.e., control group, disease group, etc). The 
individual groups may also be assigned to a category label, and in some cases (as in the hierarchical 
classifier scheme) two or more groups may be combined and assigned to the same label (i.e., the 25-, 
50- and 75% myopathic groups are assigned to the myopathic category). Even if the groups are 
labeled in this way, accuracy measures (sensitivity) are presented on a per-group basis, to allow for 
better evaluation of the consistency and robustness of each method. For instance, a method that 
performs perfectly for severely diseased patients but fails in detecting pathology in mildly diseased 
patients is not desirable. A method that performs similarly in each muscle group would presumably 
provide a better balance of performance and consistency, even if the average accuracy was the same. 
(Note: in this sense ‘balance’ is quantified by the sensitivity-specificity deviation (SSD) measure 
introduced later in this chapter.) 
Most models assume that the categories used for classification are the same as those presented to 
the decision maker (e.g., the conventional disease states), however the hierarchical model presented in 
the next section precludes this. Thus, discussions relating to the categories or class structure used to 
stratify training data will refer to the level of classification, whereas discussions relating to the clinical 
categories presented to a decision maker will refer to the level of inference (refer to Figure 5.1). The 
strata used at these two levels may or may not be the same. In the case of disease detection, the 
clinical states corresponding to the lowest stratification resolution (i.e., disease categories) were 
always reported at the inference level. However, at the classification level, different degrees of 
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resolution were considered. In fact, the main classification strategy developed can be viewed as a high 
resolution classification problem that is then reduced to the resolution required to represent the 
clinical states being studied. In the case of LOI detection, the appropriate resolution of clinical states 
to report at the inference level was unknown. This was one of the parameters that were varied, and the 
goal was to find a balance between accuracy and LOI resolution. The specific strategies and 
permutations of stratification groups for each of these cases will be described in more detail in the 
next sections. 
5.2 Characterization Strategies 
As a starting point, training and testing data were evaluated using both high-level disease 
stratification and low-level LOI stratification. Accuracy measures were based on the aforementioned 
stratification schemes, resulting in square confusion matrices. MUP feature vectors were classified 
using LDA and PD, and were aggregated using the four aggregation measures described: Arithmetic 
Mean (AM), Bayes Rule (BR), Adjusted Bayes Rule (AB), and WMLO. 
5.2.1 Accuracy of Disease Categorization 
Previous preliminary testing showed that errors made during low-level stratification were typically 
made within disease groups. As a result, a hierarchical classification scheme was developed. At the 
lowest level, each MUP is classified using a high class resolution, treating each LOI sub-strata as a 
separate class. The size of (number of conditional probabilities in) the resulting characterization 
vector is then equal to the number of LOI groups multiplied by the number of disease groups, in 
addition to the CTRL group. MUP characterizations of this form are then aggregated using one of the 
techniques mentioned above, producing a muscle characterization vector of the same size. The 
resolution of this vector is then reduced by combining the scores assigned to each of the LOI groups 
of a specific disease state. The score assigned to the CTRL category remains unchanged. In the 
current implementation, the scores corresponding to each of the LOI groups are combined by 
summation, and thus remain normalized, although they no longer reflect true conditional 




Figure 5.1: Hierarchical classification scheme applied to disease and LOI characterization 
5.2.2 Accuracy of LOI Categorization 
LOI can either be classified into discrete categories such as low and high, or it can be reported as a 
continuous value that relates to the confidence in a characterization. Since LOI is a relatively new 
concept in clinical QEMG, there is no gold standard or preferred way to present the information. 
Thus, the purpose of these methods is not only to improve accuracy for a particular method, but to 
compare the various strategies in terms of their accuracy and resolution, so that recommendations can 
be made. The first part of this section refers to identification of discrete LOI classes, which is 
analogous to the disease detection process described above. The second part attempts to evaluate 
continuous measures of LOI. There is some degree of overlap between the two strategies, since the 
discrete methods are also modified to produce a continuous score that relates to LOI. 
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Discrete LOI Categories 
One of the issues in using the high-resolution stratification above is the relatively large number of 
classes (i.e., 7 vs. 3). While the technique may improve upon the accuracy of disease detection, an 
increase in the number of classes requires a subsequent increase in the amount of total training data, 
as a sufficient number of samples is needed to represent each category. PD was shown to be 
particularly affected by training set size, and when the training pool is of insufficient size, PD is less 
accurate at estimating conditional probabilities. The underlying premise here is that accurate 
conditional probabilities are more important in determining LOI, especially in the case of continuous 
measures, but also in the case of discrete LOI classification. 
Thus, in evaluating LOI methods, a two-stage classifier was introduced. The first stage used the 
hierarchical scheme described in the previous section to determine the disease category. The second 
stage (LOI stage) then focused on predicting the LOI category corresponding to the predicted disease 
category only. The second stage only required training data for the disease category that was 
predicted in the first stage, thus reducing the number of classes to be considered. The addition of the 
control group to the training pool used in the second stage was also considered. 
For discrete LOI classification, several variations of the hierarchical scheme were applied in the 
LOI stage. The first set of techniques focused solely on relabeling and reassigning classes, in a 
manner similar to the hierarchical scheme used for disease detection.  Preliminary testing also showed 
that many of the errors in predicting LOI categories were made by incorrectly assigning muscles from 
the medium (M) LOI category as either low (L) or high (H). Thus a re-assignment strategy was 
applied that would re-label muscles originally classified as M based on the highest characterization 
score assigned to each of the L and H categories. In other words, if the M category was characterized 
with the highest score, then the second highest score was considered in order to assign a category. 
Consequently, the LOI category resolution provided at the inference level was reduced from three 
categories (L, M, and H) to two categories (L, H). In order to evaluate performance and to construct a 
confusion matrix, it was thus necessary to merge the true labels of the test muscles so that there were 
only two categories, namely L and H.  Two ways to merge the labels were considered, the first 
combined the muscles of the M group with the L group, while the second combined the muscles of 
the M group with the H group. 
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The second set of techniques focused on relabeling categories at the level of classification. For 
these techniques, the class resolution of the actual training data was reduced. Just as in the first case, 
the M group was either relabeled to be part of the L group, or relabeled to become part of the H 
group. By relabeling at the classification level, MUP and muscle characterization vectors already 
represented the actual clinical LOI states, and it was not necessary to reassign predicted categories as 
before. The true labels of the test muscles were again merged as described above. 
The main differences between the first and second sets of techniques is that in the former, the 
resolution of categories was reduced, while the classifiers still relied on a fine-resolution class 
structure and in the latter, relabeling at the classification level resulted in training the classifier with a 
coarser class-structure resolution. These differences, along with a visual depiction of the hierarchical 
stratifications, are illustrated in Figure 5.2. 
 




In addition to evaluating discrete LOI characterization performance, continuous measures relating to 
LOI were considered. Such evaluation was first introduced by Pino (Pino and Stashuk, 2008), who 
demonstrated that characterization scores of the winning category were highly correlated with LOI. 
However in that previous work, only the AM aggregation technique was evaluated. In this work, 
scores produced by AM, BR, AB and WMLO were considered. In the case of disease stratification, 
winning characterization scores were correlated with LOI for the purposes of comparison against the 
findings discussed in (Pino and Stashuk, 2008). However, these scores were shown to have 
considerable overlap and were not found to be clinically useful. As such, the stratification and 
classification schemes considered in this work were modified to produce a continuous scalar value 
representing LOI. 
The first method considered involved the two-stage classifier scheme introduced above. This 
technique was developed purely as a continuous LOI measure, and did not attempt to classify and 
assign a label based on LOI category. In the LOI stage of classification, a classifier was trained using 
the MUP data corresponding to the predicted disease category, in addition to the CTRL data. The 
disease data was not stratified any further. Thus the objective was to use the conditional probability 
assigned by the binary classification problem as a measure of LOI. If the predicted category was 
normal, then the second stage was bypassed and a score of zero was assigned for LOI. However, in 
the case of a predicted disease, the conditional probability score assigned to that category by the 
second stage LOI classifier was used, regardless of whether it was the winning score. 
For the discrete LOI classifier variants, it was necessary to apply an interpolation scheme or 
heuristic to obtain a continuous score that was a combination of the characterization scores produced 
by the aggregation process. Two types of scores produced by the hierarchical classifier were 
considered. The first method obtained LOI scores by summing the conditional probability measures 
assigned to each LOI category at the level of classification, while the second method used an 
interpolation scheme, also based on these conditional probability measures. The former was only 
applied for completeness so that the hierarchical classifier score could be compared with the standard 
disease-stratified and LOI-stratified techniques. 
The interpolation method was used in order to obtain a more intuitive continuous score, and can be 
referred to as deterministic mapping, rather than a conditional probability or measure of confidence. 
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If the number of conditional probability measures in the characterization vector was odd, the middle 
category was used as the reference, which was assigned a value of zero. Scores to the left of this value 
(i.e., scores assigned to categories representing lower LOI groups or the normal category) were 
subtracted from the reference, while scores to the right of this value (i.e., scores assigned to categories 
representing higher LOI groups) were added to the reference. The obtained value was then 
normalized by the number of classes to obtain a continuous score in the range of [0 1]. If the number 
of conditional probability measures in the characterization vector was even, the scores were split 
evenly and the midway point between the two middle categories was chosen as the reference. The 
reference value was set to zero as before. Scores assigned to categories representing lower LOI 
groups were subtracted from the reference value and scores assigned to categories representing higher 
LOI groups were added to the reference value. The value obtained was again normalized by the 
number of LOI groups considered. Equation 5.1 shows the interpolation scheme used in each of these 
cases. 
                       
   
      
        
Where 
    
                                                      
 
                                                       
  
 
P(yw | MUPs)  is the characterization score assigned to the w
th category, when scores are 
sorted by increasing LOI. 
When high-resolution stratification was used at the classification level, the same interpolation 
scheme was applied regardless of how the characterization was reported at the inference level. 
However, when muscle groups were relabeled at the classifier level, the size of the characterization 
vector was reduced, and so the interpolated continuous values were also dependent on class 
stratification. In both cases, the score was evaluated with and without the CTRL group data included 
in the training set. 
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5.2.3 Evaluation of Aggregation Measures 
For all of the above techniques, each of the aggregation measures was applied so that their relative 
performance could be evaluated. However, to study the behavior of the various aggregation measures 
it was necessary to vary the amount of evidence used in arriving at a decision. Thus the number of 
MUPs used for aggregation was varied, in increments of five, starting with five MUPs and ending 
with 25 MUPs. The accuracy and SSD of each method was evaluated for each set of muscles 
comprised of the specified number of MUPs. 
5.2.4 Validation of Methods Using Clinical Data 
The above techniques were applied to simulated data for evaluation purposes. The findings were then 
validated against the clinical MDX data described previously. LOI detection was only evaluated for 
certain methods because the hierarchical model could not be used. For the MDX data, since there 
were only two LOI categories, it was not possible to combine them and still provide an LOI 
characterization. Continuous LOI correlation was still considered. 
5.3 Evaluation of Performance 
The following section describes the measures used to evaluate the performance of methods used in 
this thesis. 
5.3.1 Accuracy and Balance between Sensitivity and Specificity 
Measures of performance that are more robust to unequal numbers of test instances across classes 
exist (Pino, 2009). For instance, Pino used sensitivity, specificity and sensitivity-specificity deviation 
(SSD) to evaluate classifier performance. SSD is used to determine how well a classifier maximizes 
(or balances) both specificity and sensitivity. Traditional measures of accuracy are biased towards the 
category that has the largest number of test muscles to be characterized (Pino, 2009). Thus, measures 
of accuracy become skewed when the proportion of disease muscles to controls is unequal. 
Sensitivity was defined as the total number of muscles characterized as having a particular disease 
divided by the total number of ‘true’ muscles having that disease. Specificity was defined as the total 




In this work, the traditional measure of accuracy is used within each disease and LOI strata. When 
considered in this way, accuracy is equivalent to sensitivity when the muscle is from a disease pool, 
and is equivalent to specificity when the muscle is from the control pool. However, since there are 
multiple disease-LOI strata, a mean accuracy is computed across all such measures, which is also 
used in the calculation for SSD. Sensitivity, specificity and SSD are reported when there is only one 
disease category, and a 3-class SSD is used in the a 3-class case. 
Total accuracy was defined as the average of sensitivity and specificity. If there was more than one 
disease category, then sensitivity measures from both disease categories were included in this 
average. 
In the two-class case, SSD was defined as: 
      
                                 
 
         
 For data sets with three categories, the term sensitivity-specificity deviation (SSD) was defined as: 
     
          
          
 




      
Where 
Anorm   is equivalent to the specificity term in equation 5.2 (i.e., normal class accuracy), 
Amyo   is the mean sensitivity across each LOI group within the myopathic category, 
Aneur  is the mean sensitivity across each LOI group within the neurogenic category, 
A  is the mean accuracy of Anorm, Amyo, and Aneur. 
5.3.2 Correlation of Muscle Scores with LOI 
Muscle characterization scores were assessed for correlation with actual LOI using Spearman 
Ranking (Duda et al., 2000), and were calculated for all characterized muscles using the score 
assigned to the true class, regardless of whether that class was correctly categorized with respect to 
disease. However, the muscles of each disease group were considered separately, and muscles from 
the CTRL (normal) group were not included in the correlation measure. The effect of including 
muscles from the CTRL group in the training set used for classification was assessed. By including 
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muscle scores from muscles that were incorrectly categorized, correlation values may be skewed, but 
it seems logical to allow these mistakes since in practice it is a plausible scenario and correlation 
assessments are not concerned with categorization accuracy. In addition to recording correlation 






The results of all tests are presented in this chapter. First, the sampling protocol is described as it 
pertains to the datasets used for evaluation and validation of the methods. Next, results pertaining to 
the improvement of disease categorization are provided, to determine if the hierarchical approach is 
able to provide better accuracy and balance across LOI groups. The analysis of methods used to 
categorize LOI into discrete classes is then presented. Here, different class hierarchies and groupings 
are considered in order to determine the ideal balance between the resolution of LOI categories and 
the accuracy with which those categories can be detected. Continuous measures of LOI produced by 
the aggregation measures described previously are then considered using the various stratification 
schemes, to determine if a particular method accurately represents LOI. Finally, the results describing 
the behaviors of the various aggregators are presented so that the suitability and necessary conditions 
of each aggregation method can be evaluated. 
6.1 Sampling and Presentation 
As discussed previously, the data used for evaluation purposes was comprised of a control state and 
two disease states, and each of the disease states was further stratified into three LOI groups, totaling 
seven groups. For validation purposes, clinical muscular dystrophy data was used in which there was 
only one disease state and two LOI groups, totaling three groups.  
6.1.1 Sampling of Data for Evaluation 
In total, 700 virtual muscles were sampled from the MUP pools for training and testing purposes. 
Each virtual muscle was comprised of a specific number of MUPs and was assigned a category label 
corresponding to the pool from which its MUPs were drawn from. For each of the LOI MUP pools, 
and for the CTRL MUP pool, 100 muscles were created using a k-fold cross-validation scheme (k = 
10). For every kth fold, the MUP pool was roughly split in half, with 150 MUPs randomly selected 
(without replacement) for training. From the remaining MUPs, m virtual muscles (m = 10) were 
created for testing by randomly selecting n MUPs per muscle without replacement, where n was the 
number of MUPs used for the particular study (in most cases n = 10). The set of n MUPs selected for 
the mth muscle was replaced before drawing subsequent muscles. This process was applied to each of 
the MUP pools, creating 10 muscles and a set of training data for each high-resolution stratification 
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group. This entire selection process was repeated for a total of k folds (k = 10), thus producing 100 
muscles for each stratification group, and 10 unique sets of training data (i.e., one per fold). To study 
variation across training sets, the muscles from each cross validation group were combined, but the 
training data corresponding to each of the k folds were kept separate, so that the muscles drawn from 
each of the k cross-validation groups were trained with unique training data. 
The same set of virtual muscles was classified using LDA and PD, and their individual MUP 
characterizations were combined using the AM, BR, AB and WMLO aggregation measures. For each 
of the desired study objectives (i.e., Disease detection, LOI detection) the same set of virtual muscles 
was used across the various stratification schemes as well. In this way, the variability across trials was 
minimized. An exception was made to this method rule when studying the effects of the amount of 
evidence (i.e., number of MUPs) on aggregation techniques because of the variations in training set 
size produced by these protocols. 
6.1.2 Sampling of Data for Validation 
To validate the findings on real world clinical data, the methods herein were applied to the MDX data 
set. This data set has a relatively low number of muscles, especially when stratified by LOI. As such, 
it would be difficult to assess characterization performance based on the actual muscles because 
accuracy measures would be very granular and variability would be high. The 10-fold cross validation 
scheme described above was thus applied to these data, creating unique training pools and virtual 
muscles for testing. For each of the LOI stratification categories, as well as the control group, 100 
virtual muscles were created, for a total of 300 muscles. 
6.2 Accuracy of Disease Categorization 
The performance results of the hierarchical classification scheme are compared with the standard 
classification methods. Both total accuracy and performance across LOI groups are considered, in 
order to evaluate accuracy and the ability to balance sensitivity and specificity. 
6.2.1 Evaluation Using Simulated Data 
In general, total accuracy for the simulated data set was exceptionally high. Using disease 
stratification, high accuracy was achieved when muscles were comprised of either 10 or 20 MUPs. 
With 10 MUPs, LDA and PD were comparable with accuracies between 94-96%. LDA had a 
significantly lower SSD that was more than half the value of the SSD for PD. These results are 
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illustrated in Table 6.1 for the case when 10 MUPs were used. Although not shown, at 20 MUPs, PD 
accuracy increased to 97% with a decreased SSD (0.04-0.08) and LDA performance remained 
unchanged. In terms of aggregation measures, all of the measures performed comparably for LDA 
(94-95%). PD accuracy values were also similar across the aggregation methods, but the SSD's were 
subject to greater variability. Bayes had the lowest SSD in both cases, with Adjusted Bayes being a 
close second. 
Table 6.1: Disease categorization accuracy for simulated data 
Method Classifier Average WMLO Adjusted Bayes Bayes 
Standard LDA 0.95 ± 0.05 0.95 ± 0.05 0.95 ± 0.05 0.94 ± 0.05 
PD 0.96 ± 0.12 0.96 ± 0.11 0.95 ± 0.10 0.95 ± 0.10 
Hierarchical LDA 0.95 ± 0.04 0.96 ± 0.05 0.96 ± 0.06 0.97 ± 0.05 
PD 0.94 ± 0.08 0.95 ± 0.11 0.95 ± 0.12 0.95 ± 0.11 
Values expressed as mean ± SSD. Categorizations are based on 10 MUPs. 
 
Table 6.2: Confusion matrix for standard stratification method (Bayes, LDA) 
 Classified As 
True Class Normal Myopathic Neurogenic 
Normal 99 0 1 
Myopathic 3 297 0 
Neurogenic 35 2 263 
Based on 100 CTRL, 300 MYO and 300 NEUR muscles. Showing 41 total errors. 
 
Examining the confusion matrix for the standard stratification method reveals the source of most of 
the errors made (see Table 6.2). Clearly, many of the muscles from the neurogenic group were 
misclassified as being normal (false negative). In contrast, a similar type of error (false positive) was 
only made 3 out of 300 times for the myopathic group. Similar trends were observed in confusion 
matrices corresponding to all classifier-aggregation method combinations.  To better understand the 
sources of these errors, it is useful to examine the accuracy (sensitivity) per muscle group (since each 
muscle group represents a specific LOI). Looking at the right-hand side of Figure 6.1 to Figure 6.4, 
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the per-group muscle accuracy is shown for standard disease-based stratification for the BR and AR 
aggregation methods for both LDA and PD. In the LDA case, the largest performance drop is seen in 
the 25% neurogenic group (NEUR-25), while for PD, a performance drop occurs in the normal 
(CTRL) group. This indicates that PD is more sensitive at detecting disease, but has poor specificity. 
LDA, on the other hand, has higher specificity and slightly poorer sensitivity. However, because this 
loss of sensitivity is localized to the NEUR-25 group, its impact is less significant when calculating 
SSD, thus LDA is better balanced with respect to both sensitivity and specificity. 
Although total accuracy and SSD are fairly high, the notable drop in either the CTRL group or the 
NEUR-25 group is undesirable as it demonstrates a clear trade-off between sensitivity and specificity. 
The hierarchical classifier was constructed for this purpose. Table 6.3 shows the confusion matrix 
produced when high-resolution (LOI) stratification is used at the level of classification. Although the 
per-class error rate is quite high, the errors are generally confined to the same disease group. For 
example, although the NEUR-25 group was misclassified as being NEUR-50 or NEUR-75 29 and 5 
times, respectively, it was only misclassified as normal (false negative) seven times. In total, only 11 
such false negatives were made across the neurogenic LOI groups. This is a substantial improvement 
over the 35 false negatives seen when using standard disease-based stratification, and is summarized 
by the confusion matrix for the hierarchical classifier (see Table 6.4). Thus, the hierarchical classifier, 




Table 6.3: Confusion matrix for high resolution (LOI) stratification (Bayes, LDA) 
 Classified As 
True Class CTRL MYO-25 MYO-50 MYO-75 NEU-25 NEU-50 NEU-75 
CTRL 88 0 0 0 10 2 0 
MYO-25 0 50 36 14 0 0 0 
MYO-50 0 41 30 29 0 0 0 
MYO-75 0 13 15 72 0 0 0 
NEU-25 7 0 0 0 59 29 5 
NEU-50 3 0 0 0 24 53 20 
NEU-75 1 0 0 0 10 21 68 
Based on 100 muscles per category. Showing 23 total errors for disease categorization. The shaded 
regions represent the category breakdown within each high-level disease state.  
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Table 6.4: Confusion matrix for hierarchical stratification method (Bayes, LDA) 
 Classified As 
True Class Normal Myopathic Neurogenic 
Normal 88 0 12 
Myopathic 0 300 0 
Neurogenic 11 0 289 
Based on 100 CTRL, 300 MYO and 300 NEUR muscles. Showing 23 total errors.  
 
In particular, total accuracy was improved by 1-4%, and SSD was decreased by 0.01-0.05 using 
LDA and 0.03-0.06 using PD. For LDA, Bayes aggregation had the lowest SSD at 0.01, and Average 
aggregation had the worst accuracy and SSD at 96% and 0.05, respectively. The opposite was 
observed for PD, where Average aggregation had the lowest SSD at 0.03. Although these results 
demonstrate improvement, their differences are subtle and do not illustrate the true benefit of the 
hierarchical approach. Examining per-group accuracy for the hierarchical classifier, depicted in the 
left-hand side of Figure 6.1 to Figure 6.4, provides insight into the level of 'balance' across individual 
LOI groups, as well as overall sensitivity and specificity. The LDA classifier using the BR 
aggregation method achieves the best balance and overall performance. For LDA, the AR aggregation 
methods still shows improvement over the standard classifier, however this improvement is not as 
substantial for the NEUR-25 group at on 0.82 compared with 0.93 for BR. For PD however, BR 
achieved very high sensitivity across all of the LOI groups, but specificity decreased by 0.03. The AR 
aggregation method achieved a better balance across groups when used with PD; however the mean 




Figure 6.1: Disease categorization accuracy by muscle group (Bayes, LDA) 
 
 
Figure 6.2: Disease categorization accuracy by muscle group (Average, LDA) 
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Figure 6.3: Disease categorization accuracy by muscle group (Bayes, PD) 
 
 
Figure 6.4: Disease categorization accuracy by muscle group (Average, PD) 
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6.2.2 Validation Using MDX Data 
In general, total accuracy for the MDX data set was reasonable, however there was more room for 
improvement as compared to the simulated data set. Using disease stratification, high accuracy was 
achieved when muscles were comprised of either 10 or 20 MUPs. With 10 MUPs, LDA and PD were 
comparable with accuracies between 84-86%. LDA and PD had comparable SSD values across all 
aggregation measures (0.09). In fact, no change in performance was noted across the aggregation 
measure when PD was used, however for LDA, AR performed marginally lower than the other 
methods. These results are illustrated in Table 6.5. Although not shown, an increase in performance 
was observed for both LDA and PD when muscles were comprised of 20 MUPs over those comprised 
of 10 MUPs. In all cases, increases of 3-5% were seen, and SSD values remained constant (0.08-
0.09). 
Table 6.5: Disease categorization accuracy for MDX Data 
Method Classifier Average WMLO Adjusted Bayes Bayes 
Standard LDA 0.85 ± 0.09 0.86 ± 0.09 0.86 ± 0.09 0.86 ± 0.09 
PD 0.84 ± 0.09 0.84 ± 0.09 0.84 ± 0.09 0.84 ± 0.09 
Hierarchical LDA 0.85 ± 0.06 0.89 ± 0.03 0.90 ± 0.01 0.91 ± 0.01 
PD 0.85 ± 0.06 0.85 ± 0.08 0.85 ± 0.09 0.85 ± 0.09 
Values expressed as mean ± SSD. Categorizations are based on 10 MUPs. 
Examining the confusion matrix for the standard stratification method (Table 6.6) reveals that most 
of the errors made were in the disease group. While only 3 out of 100 normal muscles were 
misclassified  as myopathic (false positive), 40 out of 200 muscles were misclassified as normal (false 
negative). Similar trends were observed in confusion matrices corresponding to all classifier-
aggregation method combinations.  To better understand the sources of these errors, it is useful to 
examine the accuracy (sensitivity) per muscle group (since each muscle group represents a specific 
LOI). Looking at the right-hand side of Figure 6.5 to Figure 6.8, the per-group muscle accuracy is 
shown for standard disease-based stratification for the BR and AR aggregation methods for the LDA 
classifier.  As expected, the largest performance drop is seen in the low myopathic group (MYO-L). 
Accuracy for the CTRL and MYO-H groups was high because the ability to discriminate between 
normality and disease is improved when the disease has significantly progressed. 
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Table 6.6: Confusion matrix for standard stratification method - MDX data (Bayes, LDA) 
 Classified As 
True Class CTRL MYO 
CTRL 97 3 
MYO 40 160 
Based on 100 CTRL and 200 MYO muscles. Showing 43 errors.  
 
Although the SSD is rather low, it is clear from these plots that disease categorization is not well 
balanced across LOI groups. Just as with the simulated data set, there is a clear trade-off between 
sensitivity and specificity. 
Table 6.7 shows the confusion matrix produced when high-resolution (LOI) stratification is used at 
the level of classification. Although the per-class error rate is quite high (but not as high as it was for 
simulated data), the errors are generally confined to the same disease group. There was a significant 
drop in the number of false negative errors (17 in total) compared with the low-resolution 
stratification method. However, this improvement came at a cost of seven additional errors in the 
CTRL group (false positive). In total, 27 errors were made which is a substantial improvement over 
the 43 errors made when using standard disease-based stratification, as seen in the confusion matrix 
for the hierarchical classifier (see Table 6.8). Thus, the hierarchical classifier, constructed on this 
basis, was able to improve performance. 
In particular, total accuracy was improved by 1-5%, and SSD was decreased by 0.03-0.08 using 
LDA. A small increase of only 1% and a decrease in SSD of 0.01-0.03 was observed using PD. For 
LDA, BR aggregation had the highest accuracy (0.91) and lowest SSD at 0.01, and AR aggregation 
had the worst accuracy and SSD at 0.85 and 0.09, respectively. The opposite was observed for PD, 
where Average aggregation had the lowest SSD at 0.06, although total accuracy was unchanged 
across the aggregation methods. With the exception of the BR-LDA combination, these results only 
demonstrate a marginal improvement that does not illustrate the true benefit of the hierarchical 
approach. Examining per-group accuracy for the hierarchical classifier, depicted in the left-hand side 
of Figure 6.5 to Figure 6.8, provides insight into the level of 'balance' across individual LOI groups, 
as well as overall sensitivity and specificity. The LDA classifier using the BR aggregation method 
achieves the best balance and overall performance. For LDA, the AR aggregation method provides an 
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improvement, albeit not as substantial, for the MYO-L group at 0.62 compared with 0.83 for BR. For 
PD however, BR achieved very high sensitivity across the LOI groups, but specificity was very low 
(0.63). The AR aggregation method achieved a much better balance across groups, however the 
improvement was not as remarkable as it was for the BR-LDA combination. These trends were quite 
similar to those seen in the simulated data set. 
Table 6.7: Confusion matrix for LOI stratification - MDX data (Bayes, LDA) 
 Classified As 
True Class CTRL MYO-L MYO-H 
CTRL 90 10 0 
MYO-L 17 77 6 
MYO-H 0 8 92 
Based on 100 muscles per category. Showing 27 total errors for disease categorization. 
 
Table 6.8: Confusion matrix for hierarchical stratification method - MDX data (Bayes, LDA) 
 Classified As 
True Class CTRL MYO 
CTRL 90 10 
MYO 17 183 





Figure 6.5: Disease categorization accuracy by muscle group - MDX Data (Bayes, LDA) 
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Figure 6.7: Disease categorization accuracy by muscle group - MDX Data (Bayes, PD) 
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6.3 Accuracy of LOI Categorization 
The accuracy with which individual LOI categories can be detected is considered here. Various 
stratification methods are applied to determine if an optimal combination of class grouping and 
classification method yields adequate performance. 
6.3.1 Evaluation Using Simulated Data 
As mentioned briefly in the previous section, the categorization accuracy for LOI-group stratification 
was quite low. In particular, total accuracy was quite poor, with values ranging from 57-60% when 
using 10 MUPs and 57-64% when using 20 MUPs for LDA. Similar values were recorded for PD, 
ranging from 54-60%. SSD values were large in all cases, ranging from 0.12-0.26. Muscles with 10 
MUPs classified by PD had the lowest SSD values (0.12-0.13) except for Average aggregation (0.17), 
which also had the highest SSD for all methods. When 20 MUPs were used with PD, only a slight 
rise in SSD (0.18) was noted, however this is of little significance in light of the poor performance 
overall. A general trend of a slight increase in accuracy with more evidence (more MUPs) was 
observed. The last row of Table 6.9 summarizes categorization accuracy for each classifier and 
aggregation method combination. 
The two-stage classifier only had marginally better performance than the standard LOI-group 
stratification method. Since the error rate between myopathic and neurogenic groups was low, this 
was an expected finding (see Table 6.7). However, it is interesting to see that SSD measures actually 
increased substantially from 0.12-0.20 to 0.20-0.24. The increase was greater for PD than for LDA, 
but was nonetheless significant for both. Despite these increases, the two-stage method was still used 
when applying the various LOI stratification schemes because it greatly reduces classification 
complexity when the number of LOI groups is high (greater than 2). A comparison of these two 
stratification methods is provided in the last two rows of Table 6.10. 
Re-examining the confusion matrix in Table 6.7 in terms of LOI accuracy, it is clear that applying 
the hierarchical method to any two adjacent LOI groups would result in better accuracy. However, in 
doing so, the number of clinical LOI states to report would be reduced, and the error rates among 
these is still substantial. Nonetheless, from a visual inspection of the errors, it is suggested that 
combining the 25- and 50- percent LOI groups would be optimal. In fact, the highest total accuracy 
was obtained when the true labels for the low and medium LOI groups were combined to form a 
single class. The optimal strategy was to re-assign muscles classified as medium LOI to either the low 
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or high LOI categories, depending on which category had the second-highest characterization score. 
For this strategy, the re-assignment was performed at the level of inference (and after classification). 
When the 25- and 50- percent LOI groups were combined prior to classification (i.e. used to re-train 
the classifier), a performance improvement was also observed, although to a lesser degree as 
compared to the re-labeling-only method. 
For this optimal method, accuracy was in the range of 71-77% for LDA and 67-74% for PD. For 
both classifiers, SSD values were between 0.10 and 0.18 for WMLO and the Bayes-based aggregation 
methods, however Average aggregation had both the lowest accuracy and highest SSD (67%, 0.25). 
When controls were not included in classifier training, LDA accuracy fell by 2-6% for the more 
extreme aggregators, but increased by 3% for Average aggregation. Average aggregation SSD also 
dropped to 0.14, while SSD for the other methods remained the same. PD accuracy was quite poor for 
all methods except Average aggregation (58% vs. 64%), but even this was significantly lower that the 
accuracy obtained with the control group included. It should be noted however, that Average 
aggregation had much more consistent performance across all of the methods tested. 
When the true labels of the medium and high LOI groups were combined to represent a single 
class, accuracy was still relatively high (71%) but SSD measures increased to 0.23. When the 
combined class structure was used to train the second stage classifier, accuracy was slightly poorer 
than re-labeling alone, with values in the range of 66-71%. SSD was also higher. The worst 
performance was obtained when the highest resolution of class stratification was used (i.e., individual 
LOI groups) regardless of whether the control group was included or not. PD consistently had slightly 
lower performance (lower accuracy and higher SSD) regardless of the method used. 
While the exhaustive set of stratification combinations was analyzed, only the two best methods are 




Table 6.9: LOI categorization accuracy of optimal methods - simulated data (Bayes, LDA) 
Method Classifier Average WMLO Adj. Bayes Bayes 
Re-label Only 
(CTRL/LM/H) 
LDA 0.71 ± 0.17 0.75 ± 0.14 0.76 ± 0.12 0.77 ± 0.12 




LDA 0.66 ± 0.20 0.68 ± 0.18 0.70 ± 0.16 0.71 ± 0.15 





LDA 0.58 ± 0.24 0.60 ± 0.23 0.60 ± 0.22 0.61 ± 0.22 





LDA 0.57 ± 0.20 0.60 ± 0.17 0.60 ± 0.16 0.60 ± 0.17 
PD 0.54 ± 0.17 0.55 ± 0.13 0.54 ± 0.12 0.54 ± 0.13 
Values expressed as mean ± SSD. Categorizations are based on 10 MUPs. 
 
Figure 6.9 and Figure 6.10 illustrate per-group categorization accuracy for the optimal stratification 
strategy compared with the two-stage LOI classifier. Notable improvements are observed, and the 
ability to categorize low and high LOI states is well balanced across most muscle groups, especially 




Figure 6.9: LOI categorization accuracy by muscle group - simulated data (Bayes, LDA) 
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6.3.2 Validation Using MDX Data 
The total accuracy of the high-resolution (LOI group) stratification method was much higher than that 
of the simulated data set. Specifically, total accuracy was better for LDA, especially with 20 MUPs, 
with Bayes and Adjusted Bayes aggregation reaching maximum accuracy and lowest SSD values 
(93%, 0.02). PD had an accuracy of 87-88% with SSD values of 0.08-0.09. For LDA, Average 
aggregation had the worst performance at 84% and an SSD of 0.12; however for PD there was no 
difference among the aggregation methods. Per-class accuracy was lowest in the low LOI group for 
both LDA and PD, and increased significantly (10%) with 20 MUPs. PD also had lower performance 
in the control group (72-86%). Of particular interest is the fact that sensitivity in detecting muscles 
drawn from the low LOI group improved by 12-21% for PD and 5-15% for LDA. While the 
improvement for PD came at a cost of specificity (down 8-21%), this was not the case with LDA. 
As described in the methods section, the hierarchical classifier could not be validated on the MDX 
data since it was only stratified into two LOI categories. However, it was possible to evaluate the two-
stage classifier, to determine the best stratification for the second stage. The optimal stratification 
scheme for the second stage was to use only the low and high LOI groups in a 2-class training set 
when the LDA classifier was used. Accuracy using this method was 88-89% and SSD values ranged 
from 0.01-0.02 for LDA. For PD, the optimal stratification scheme for the second stage was to use the 
low and high LOI groups, as well as the CTRL group, in a 3-class training set. Accuracy using this 
method ranged from 83-87% but SSD was much higher (0.05-0.06). For both classifiers, AR had the 
best performance. This performance was only marginally poorer than when disease-based 





Table 6.10: LOI categorization accuracy of two-stage classifier - MDX Data (Bayes, LDA) 
Method Classifier Average WMLO Adj. Bayes Bayes 
Two-Stage  
(L/H) 
LDA 0.89 ± 0.01 0.88 ± 0.02 0.88 ± 0.02 0.88 ± 0.02 




LDA 0.83 ± 0.09 0.87 ± 0.05 0.87 ± 0.04 0.86 ± 0.03 




LDA 0.88 ± 0.06 0.89 ± 0.05 0.89 ± 0.05 0.89 ± 0.05 
PD 0.85 ± 0.08 0.87 ± 0.06 0.87 ± 0.06 0.87 ± 0.06 
Values expressed as mean ± SSD. Categorizations are based on 10 MUPs. 
 
Figure 6.11 and Figure 6.12 show a comparison of per-group categorization accuracy for the two 
optimal stratification strategies used in the two-stage LOI classifier. In Figure 6.11, notable 
improvements in balance across muscle groups are observed for LDA using only the L and H 
categories, while in Figure 6.12, improvements in balance across muscle groups are seen using the 




Figure 6.11: LOI categorization accuracy by muscle group - MDX data (Bayes, LDA) 
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6.4 Continuous Measures of LOI 
Previous works by Pino showed that measures of confidence correlate well with LOI when using 
simulated data (Pino et al., 2008). As such, similar correlation studies were performed here using 
Spearman's Ranking Correlation Coefficient. 
6.4.1 Evaluation Using Simulated Data 
The muscle characterization score relating to confidence was first assessed. When 10 MUPs were 
used, correlation values were quite poor in general; however the neurogenic category using the LDA 
classifier was significantly better than the other methods with a value of 0.62. This value was 
obtained when the data was stratified by disease category. Using the other stratification methods 
resulted in similar values. Myopathic correlation values were extremely low, and often negative. No 
stratification method was significantly better than any of the others. PD correlation scores were 
consistently poorer than LDA correlation. As the number of MUPs was increased, correlation 
improved for the neurogenic category, but remained the same for the myopathic category. Figure 6.13 
illustrated this increasing trend for the neurogenic case. 
When discrete LOI was considered, an interpolation scheme was used to compute a scalar measure 
that was believed to relate to LOI. This measure resulted in a significant increase in correlation, with 
a maximum value of 0.59 for the myopathic category, and 0.74 for the neurogenic category. For both 
categories, this optimal correlation was produced using the Average aggregation method. This high 
correlation was realized using training data that was stratified by LOI group, without including the 
control group. When the low and medium classes were combined prior to training, correlation was 
only slightly reduced, giving the second highest performance. These results are summarized in Table 
6.11. 
Figure 6.14 to Figure 6.17 illustrate correlation by plotting muscle scores against of the true LOI 
category. For the neurogenic category, and using the LDA classifier with AB or AR aggregation 
methods (Figure 6.14 and Figure 6.15), the tendency is for muscle scores to increase with LOI. A key 
difference between these methods, however, is that the AB scores are much closer to 1 in all cases 
while the AR scores occupy a much lower range. While many of the AB scores saturate, the 
saturation effect is not as bad as with BR (see Figure 6.16). WMLO produced a fairly diverse spread 
of values, but was not correlated well. Figure 6.17 illustrates muscle scores produced by the 
interpolation scheme mentioned previously. These scores are not true conditional probabilities, and 
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only represent a deterministic mapping. However, they score reasonably well in terms of correlation 
as indicated in the plot (see figure). 
In general, the correlation plots reveal that there is considerable variation in muscle score, resulting 
in significant overlap across LOI groups. 
 
 














































Table 6.11: LOI correlation for best stratification methods - simulated data (Bayes, LDA) 
Method Classifier Category Average WMLO Adj. Bayes Bayes 
Re-label Only 
(LM/H) 
LDA Myopathic 0.59 0.57 0.58 0.58 
 Neurogenic 0.74 0.71 0.72 0.71 
PD Myopathic 0.65 0.58 0.60 0.58 
 Neurogenic 0.62 0.49 0.53 0.48 
       
Re-Train 
(CTRL/L/M/H) 
LDA Myopathic 0.54 0.55 0.57 0.56 
 Neurogenic 0.74 0.72 0.73 0.72 
PD Myopathic 0.48 0.53 0.54 0.55 
 Neurogenic 0.64 0.57 0.60 0.57 
       
Standard (3-class) 
(CTRL/MYO/NEUR) 
LDA Myopathic -0.13 -0.35 -0.24 -0.26 
 Neurogenic 0.61 0.60 0.62 0.61 
PD Myopathic 0.00 -0.10 -0.02 -0.01 
 Neurogenic 0.48 0.44 0.46 0.44 




Figure 6.14: Neurogenic muscle scores by LOI group - simulated data (AB, LDA)
 




Figure 6.16: Neurogenic muscle scores by LOI group - simulated data (BR, LDA)
 
Figure 6.17: Interpolated myopathic muscle scores by LOI group - simulated data (AB, LDA) 
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6.4.2 Validation Using MDX Data 
Correlation values produced by the MDX data set were surprisingly well correlated with LOI, unlike 
for the simulated data case. When 10 MUPs were used, the highest correlation was achieved by the 
LDA classifier and AR aggregation method combination. However, performance was quite close 
using the other aggregation methods. LDA again had higher correlation values than PD. As the 
number of MUPs was increased, correlation improved very slightly, remaining fairly constant for 
MUP numbers greater than 10. Figure 6.18 illustrates this trend. The best correlation was obtained 
when only two classes (L and H) were used to train the classifier. These results are summarized in 
Table 6.12. 
Figure 6.19 and Figure 6.20 illustrate correlation by plotting muscle scores against of the true LOI 
category. When the AB method was used, muscle scores for the L group occupied the entire range of 
possible values, while scores for the H group were quite close to one. Using the AR aggregation 
method, greater separation was observed between the groups (see Figure 6.19). In fact, only a few 
assigned scores seem to overlap, and it seems that scores assigned to the two LOI categories are quire 
separable. 
 
































Table 6.12: LOI correlation for optimal stratification methods - MDX data (Bayes, LDA) 
Method Classifier Average WMLO Adj. Bayes Bayes 
Two-Stage  
(L/H) 
LDA 0.86 0.85 0.85 0.85 




LDA 0.85 0.85 0.85 0.85 




LDA 0.82 0.82 0.82 0.82 
PD 0.78 0.77 0.77 0.77 
Values expressed as mean ± SSD. Categorizations are based on 10 MUPs. 
 
 




Figure 6.20: Myopathic muscle scores by LOI group - MDX data (AR, LDA) 
 
6.5 Aggregation Measures 
The accuracy of disease categorization as a function of the amount of evidence is presented next.  
6.5.1 Evaluation Using Simulated Data 
The results corresponding to the data used for evaluation are presented. Figure 6.21 to Figure 6.24 
show categorization as a function of the number of MUPs for the LDA and PD classifiers using the 
standard or hierarchical stratification methods. Accuracy for each of the aggregation measures is 
plotted on the same graph, and represents the average accuracy of the CTRL and NEUR-25 muscle 
groups. Only these groups were chosen because they accentuate the differences as the other groups 
had accuracy values close to 1 and did not vary across methods. 
When standard disease stratification was used, the aggregation measures are quite close for LDA. 
For PD however, BR, AB, and to a lesser extent WMLO, tend to perform better than AR. WMLO 
seems to reflect the average trend, lying roughly in the middle of the other methods. The accuracy of 
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PD as compared to LDA is slightly higher for all numbers of MUPs. However, it should be 
emphasized that these results are based solely on the CTRL and NEUR-25 groups, and therefore are 
not contradictory to the results presented in the previous section. Another notable finding is that for 
LDA, when 25 MUPs are used, accuracy actually drops slightly compared to when 20 MUPs are 
used. This is contrary to the expectation that accuracy should improve with more evidence. Also, for 
PD, the aggregation measures are ranked as expected at lower MUP numbers, however the trend fails 
at 25 MUPs. For LDA, the measures are not ranked as expected until there are at least 25 MUPs, 
however these differences are less significant since performance is quite comparable across each 
method. 
When the hierarchical method is used, very different behaviors are observed across the classifiers 
and aggregation methods. For the LDA classifier, performance is drastically improved when the 
number of MUPs is greater than 10 for WMLO, AB, and BR. The performance improvement tapers 
off as the number of MUPs exceeds 15. Note how these measures practically overlap each other. The 
AR method, on the other hand, lags considerably in terms of accuracy. In fact, for higher MUP 
numbers, it seems to follow a similar trajectory as in the standard stratification method, including the 
notable dip at 25 MUPs. Despite significant overlap, it appears that the rankings of each method are 
as expected. For the PD classifier, the opposite effect is observed. Mainly, the AR method excels, 
particularly for MUP numbers greater than 15, while the other methods perform quite closely to each 
other. At 20 MUPs, the methods are all equivalent, however AR finishes on top at 25 MUPs. Again, 
the aggregation measures are ranked as expected, except at very low MUP numbers. The average 




Figure 6.21: Average accuracy vs. number of MUPs – simulated data (Standard, LDA) 
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Figure 6.23: Average accuracy vs. number of MUPs – simulated data (Hierarchical, LDA) 
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6.5.2 Validation Using MDX Data 
The accuracy of disease categorization as a function of the amount of evidence is presented next. 
Figure 6.25 to Figure 6.28 show categorization as a function of the number of MUPs for the LDA and 
PD classifiers using the standard or hierarchical stratification methods. Accuracy for each of the 
aggregation measures is plotted on the same graph, and represents the average accuracy of the CTRL 
and MYO-L muscle groups. Only these groups were chosen because they accentuate the differences 
as the MYO-L had accuracy values close to 1 and did not vary across methods.  
When standard disease stratification was used, the aggregation measures were quite close and 
overlapped for LDA. For PD however, BR, AB, and WMLO are completely overlapped and tend to 
perform better than AR. The accuracy of PD as compared to LDA is slightly lower for all numbers of 
MUPs except for 25 MUPs, where there is an increase. Another notable finding is that for LDA, when 
25 MUPs are used, accuracy actually drops slightly compared to when 20 MUPs are used. This 
characteristic was also observed in the simulated data set and is contrary to the expectation that 
accuracy should improve with more evidence. No comments can be made about the ranking of 
aggregation methods because of the significant overlap. 
When the hierarchical method is used, very different behaviors are again observed across the 
classifiers and aggregation methods. For the LDA classifier, performance is drastically improved 
when the number of MUPs is greater than 15 for WMLO, AB, and BR. The AR method, on the other 
hand, lags considerably and seems to follow a similar trajectory as with the standard stratification 
method, including the notable dip at 25 MUPs. The rankings of the aggregation methods are as 
expected, except for the fact that AB and BR tend to switch places for MUP values of 15 or more. 
However, given the closeness of these two methods, this change of position is not significant. 
For the PD classifier, performance improves marginally as compared to the standard stratification 
method. However, there is an unexpected drop in performance at 25 MUPs for all of the aggregation 
measures. Interestingly, the rankings of each method are in the proper order, with AR showing the 
highest accuracy, despite the fact that this accuracy is lower than that of the standard classifier. The 





Figure 6.25: Average accuracy vs. number of MUPs – MDX data (Standard, LDA) 
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Figure 6.27: Average accuracy vs. number of MUPs – MDX data (Hierarchical, LDA) 
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In order to improve the accuracy with which disease categories could be detected, a hierarchical 
stratification strategy was evaluated. The findings related to this strategy are evaluated to determine if 
a significant improvement was observed. Next, the various LOI strategies are discussed to identify the 
optimal combination that is able to provide clinicians with useful information relating to LOI, and 
with reasonable accuracy. Continuous measures of LOI are shown to be quite poor in general, and 
their efficacy in provided clinically relevant information is considered. Finally, an analysis of the 
behaviors of the various aggregators is able to provide valuable insight in selecting an appropriate 
method for use in a CDSS. 
7.1 Accuracy of Disease Categorization 
The accuracy of disease categorization is discussed in terms of total accuracy, as well as the accuracy 
across individual LOI groups. A classifier that performs reasonably well across all categories is 
desired. 
7.1.1 Evaluation Using Simulated Data 
In general, the accuracy of disease categorization was considerably high, with total accuracy above 
95% in most cases. Although some changes were observed, there is very little difference in 
performance whether 10 or 20 MUPs are considered. Global performance (that is, performance across 
all muscle groups) was high for two reasons: first, because the underlying classification problem was 
not inherently difficult (simulated data was defined to have large increments with respect to LOI), and 
secondly, because poorer performance in any one of the muscle groups is compensated for by high 
accuracy in the other groups. Thus global performance alone is insufficient for describing the clinical 
performance of any particular method. An analysis of the per-class accuracies revealed that there was 
a particular group, specifically the NEUR-25 group, which had significantly poorer accuracy than the 
other groups. This is typical in the case of neurogenic disease because in the earlier stages of 
progression there is a lower chance of MU restructuring and some MU's may even appear myopathic 
with respect to certain features. The latter was not the case because there were very few errors made 
between disease categories. Re-examining the feature plots for the various LOI groups of the 
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neurogenic category reveals that there is in fact considerable overlap between the CTRL and NEUR-
25 group. However, even with this overlap, fairly high accuracy was obtained. 
While the performance is not inherently bad, and may be acceptable from a pattern recognition 
perspective, it is not clinically acceptable to have a significant drop in performance in one specific 
muscle group. In the area of disease detection, it is often the case that early detection leads to more 
effective intervention and treatment and thus a higher cost might be associated with miss-detection of 
a lower level of disease. However, the contrary may also be true: higher specificity may be desired 
over higher accuracy of lower levels of disease because a false positive might cause undue stress and 
mental anguish for the patient. Despite the costs, however, it is clear that a better balance between 
sensitivity and specificity should be sought. 
The hierarchical scheme was able to provide such a balance, showing a significant increase in 
detection accuracy of the N-25 group, without a significant loss of accuracy in the other groups. The 
improvement was more significant for LDA than for PD as PD already had good performance using 
disease stratification. A likely explanation for this is the fact that PD can detect complex patterns in 
the data and thus form non-linear decision boundaries, giving it an advantage over the linear 
boundaries formed by LDA. By increasing the stratification resolution, the number of training 
samples per class is decreased. Since PD is more dependent on training set size in order to detect 
significant patterns, the ability for improvement when using the hierarchical classifier is subject to the 
availability of a sufficiently large set of training data. 
Nonetheless, in the case of LDA, and to a smaller extent for PD, the hierarchical method offers the 
ability to train the classifier with exemplary data that is more condensed and subject to less 
variability. The advantage of this is that better discrimination is possible between low levels of LOI 
and other categories. By recognizing the smaller variations in the distribution of MUP features for 
low LOI, sensitivity and specificity become better balanced. In contrast, when low LOI MUPs are not 
labeled as such, they become overshadowed by adjacent classes, resulting in a higher specificity at a 
cost of sensitivity. 
7.1.2 Validation Using MDX Data 
Similar observations were made in both the simulated data and real-world data. Specifically, the 
hierarchical method was able to significantly improve upon the balance of sensitivity and specificity. 
The magnitude of the improvement was slightly higher for the real-world data, but a large part of this 
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is attributed to having stratified the data into a smaller number of LOI categories, resulting in an 
easier classification problem. 
Again, the LDA classifier with BR aggregation had the best overall performance. However, the 
contrast between this and using the PD classifier with AR aggregation was more obvious with this 
data set. In particular, when LDA was used, BR provided great performance but AR did not. Likewise 
when PD was used, AR provided good (but not great) performance while BR did not. These 
differences do not suggest that one method is better than the other, but rather highlight the different 
behaviors that depend on the quality of the evidence. When the standard disease stratification method 
was used, PD had slightly better performance than LDA in terms of better SSD. However, with the 
hierarchical method, only the AR method had significant improvement for PD because the quality of 
the evidence was less accurate. In other words, since there was fewer training data per class, a larger 
number of MUPs were incorrectly classified with false (inaccurate) confidence. The specific behavior 
of these aggregation methods will be discussed in greater detail in a later section of this chapter.  
7.2 Accuracy of LOI Categorization 
The optimal combinations of class structure and classification method are now discussed. For an LOI 
categorization method to be useful, it must be able to categorize LOI with acceptable accuracy, while 
reporting a sufficient range of clinically useful LOI states at the level of inference. 
7.2.1 Evaluation Using Simulated Data 
As seen in the results section, the accuracy of categorization when high-resolution stratification is 
used is quite poor. This is expected because, as seen in the distribution plots, there was a high degree 
of overlap in the feature distributions of the LOI groups. Thus, attempting to characterize clinical LOI 
at this level of stratification is not practical. The modified hierarchical strategy was able to improve 
on the accuracy of LOI detection, as long as the number of LOI groups was reduced from three to 
two. In particular, the strategy of re-labeling muscles categorized as having medium LOI proved to be 
most effective. The re-labeling was accomplished by selecting the second-highest characterization 
score and using that category as the assigned LOI label. 
When the training data was re-labeled prior to training the second stage classifier, the performance 
improvement was not as significant. By doing so, the number of errors made between the CTRL 
group and the high LOI group increased, since the lower LOI groups were not represented as 
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concisely. Pattern Discovery did not provide as much of an increase in performance for this optimal 
LOI stratification. Again, this is likely due to an insufficient number of training samples when high-
resolution stratification is used. Thus, it is more likely that PD would out-perform LDA if the training 
data for the low and medium groups was combined prior to classifier training.  
The two-stage classifier method was used and is recommended because it allows for the possibility 
of different stratification strategies and aggregation techniques to support the two objectives of 
disease and LOI characterization. Further, by only using training data for the category predicted by 
the first stage, the number of classes in the second stage is reduced significantly, thus reducing 
computational complexity. In the case of two disease states and three LOI categories in each, the 
number of classes is reduced from seven to three or four, depending on the strategy. 
This strategy represents a compromise between the number of clinical LOI states and the accuracy 
with which each of those states can be categorized. 
7.2.2 Validation Using MDX Data 
The MDX data could not be used to validate the hierarchical method when characterizing LOI. Since 
there were only two LOI categories present, it was not possible to reduce the stratification resolution 
and still report a clinical LOI state. Thus, only choices in stratification schemes were limited to 
whether or not the CTRL group was to be included. The two-stage classifier was shown to work best 
when only the two LOI states were used in classifier training. Thus the problem was reduced to a 
binary decision. The LDA classifier, using BR or AB aggregation methods, provided maximal 
performance. PD performance was slightly lower, but nonetheless acceptable. However, while the 
improvement for PD came at a cost of specificity, this was not the case with LDA. Thus, the ability 
for LDA to balance the accuracy in categorizing low and high LOI states while improving 
performance makes it a suitable candidate for the second stage LOI classifier. Because the classifier is 
making a binary decision, transparency of the method is less of an issue, and visualization of the 
decision space may even be possible with sufficient feature reduction. 
7.3 Continuous Measures of LOI 
Although previous work has shown strong correlation between muscle characterization confidence 
and LOI, the results presented here suggest that it is not a very useful measure. Even if a score is 
highly correlated, the overlap of scores across LOI groups, as depicted in the correlation plots, makes 
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it difficult to interpret an assigned score. At most, the range of score values might make it possible to 
establish certain intervals for a given LOI group, but the likelihood of a muscle falling into the correct 
interval would be quite low. As such, it is not clinically useful to report an LOI measure in this way.  
The interpolated scores, while not being true conditional probabilities, did improve correlation. 
However, the degree of improvement still does not increase the utility of a continuous measure 
because they are still subject to the same amount of overlap. These limitations make it clear that 
continuous measures of LOI are not clinically viable. 
With this in mind, a continuous measure is still sought. Specifically, when coupled with the 
discrete LOI classification studied in the previous section, a continuous measure could be thought of 
as a measure of confidence in the predicted LOI state. Thus, if two or more LOI states had high 
confidence, this might indicate that the true LOI state is somewhere in the middle of the range 
spanned by the specified LOI states. In contrast, if only a single LOI state had a high measure of 
confidence, then the true LOI would likely fall within this category. If such a reporting scheme were 
developed, then an interpolated continuous measure of LOI value could be incorporated into a user 
interface to aid in presenting the data. 
The correlation results from the MDX data show much more promise as continuous measures, 
however these results are only limited to two LOI categories. Further study would be needed on larger 
clinical datasets in order to determine if these findings are significant. 
7.4 Aggregation Measures 
The behavior of aggregation measures as a function of the amount of evidence (number of MUPs) is 
discussed. By understanding the limitations of each method an appropriate method can be selected 
based on the level of conservativeness required by the system operator.  
7.4.1 Evaluation Using Simulated Data 
When using standard disease stratification, the ability for PD to discriminate between CTRL and 
NEUR-25 is slightly better than that of LDA. This is likely due to the fact that with this type of 
stratification, the number of training samples per class is adequate in order for PD to perform 
optimally. As such, PD is able to detect complex patterns in the training data that help discriminate 
between these categories. The linear decision boundary produced by LDA is not able to accomplish 
this as well. MUPs that fall into the low LOI region are assigned a lower conditional probability value 
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because they are closer to the discriminant function. As such, although a MUP might be 
representative of an exemplary MYO-25 MUP, the amount of evidence it provides to the decision is 
underweighted. As the amount of evidence is increased, there is a higher chance of low-confidence 
MUPs appearing due to a lack of a crisp definition of abnormality. Thus, there are fewer outliers 
present to influence the decision, and the AR method comes out on top. However, when 25 or more 
MUPs are considered, the chance of observing random outliers in either disease category is increased, 
and the likelihood of a miss-classification is increased, especially in the less conservative measures. 
Since PD is able to detect higher order patterns, it is capable of producing more accurate conditional 
probabilities. As such, the outlier MUPs allow the more extreme aggregation methods to converge on 
a decision. AR still performs reasonably, but under-weights these highly confident MUPs until 
enough of them are present (i.e., 25) in order to make a decision. The WMLO seems to provide a 
good compromise among the methods, performing reasonably well but not jumping to conclusions 
too early on. 
The hierarchical method resulted in a significant improvement in accuracy for LDA. However, the 
AR method did not improve as much as the other aggregation measures. This indicates that LDA is 
producing better conditional probability estimates, and thus correct outliers, that allow the more 
extreme aggregators to make correct decisions with fewer pieces of evidence (i.e., smaller number of 
MUPs). The AR method requires many more MUPs (20 or more) before its accuracy is maximized, 
but then it drop at 25 MUPs. Given the mixture of MUPs from the normal and diseased categories 
present in a low LOI muscle, the AR method is too conservative and discounts the outliers that 
represent a diseased state. 
For PD, the overall improvement seen by the hierarchical classifier is less pronounced. As well, the 
AR method performs better than the others which is the converse of the disease stratification method. 
By increasing the stratification resolution, PD suffers from a lack of training data and so the 
conditional probabilities are calculated less accurately. As such, the more extreme aggregators falsely 
rely on the presence of outliers. The improved performance of the AR method suggests that a more 
conservative aggregator is appropriate under these circumstances. 
To summarize, BR and AB are quicker to jump to conclusions about the presence of abnormality, 
in a manner which is essentially akin to counting outliers. While this approach works well both in 
theory and practice, it is highly dependent on the assumption that the quality of the data (specifically 
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the estimates of conditional probability) is high. Averaging and methods based on it (i.e., WMLO) are 
more conservative and typically require more evidence before they make a decision. However, given 
the variability of MUPs within a muscle, the AR technique will always under-perform compared to 
the BR-based methods because it is less influenced by valuable outlier information, subject to the 
accuracy of such information. In contrast, if assurances about data quality cannot be made, BR-based 
methods will be more susceptible to errors and will not fail gracefully when a decision cannot be 
made with certainty. Under most circumstances, the aggregation methods seem to be ranked in the 
expected order, with the AB and WMLO methods between the AR and BR strategies. As such it 
might be reasonable to expect that either AB or WMLO would be a suitable choice for decision 
making when the methods are generalized to new data. 
7.4.2 Validation Using MDX Data 
The findings in the real-world dataset are closely aligned with those obtained from simulated data. A 
'dip' in performance was also observed when using LDA with 25 MUPs. The explanation for this is 
the same as above. Similar trends were observed between the two classifiers, as well as across the 
different stratification methods. In particular, PD performed as well as LDA for higher MUP 
numbers, and the more extreme aggregators out-performed AR since confidence scores calculated by 
PD are more accurate when sufficient training data is provided. When the hierarchical method is used, 
a major improvement is seen for LDA for the extreme aggregators, just as in the simulated case. 
However, for PD, there is a significant drop in performance, although the AR method still does 
slightly better than the other methods. The drop in performance can also be explained by lower 
accuracy of conditional probability estimates, however it seems that there is another factor to 
consider: Looking at the distribution plots of this data set, there is considerable overlap between the 
CTRL and MYO-L groups. In the simulated case, the overlap is more symmetric across the LOI 
groups. However for the MDX data, there is more overlap between the CTRL and MYO-L groups 
than there is between the MYO-L and MYO-H groups. Thus there is greater confusion (and higher 
number of errors) made between the former pair. This, combined with the fact that the number of 
training samples are lower, results in less accurate estimations of MUP confidence (i.e., incorrect 
conditional probability estimates), as well as greater confusion in MUP characterizations. The 
combined effect results in lower performance that cannot be sufficiently compensated for by the 





A hierarchical stratification scheme was evaluated and validated against real-world clinical data. 
When the method was applied to the characterization of clinical disease states, the hierarchical 
scheme was able to significantly improve upon standard classification methods. The improvement 
was realized as a balance in detection accuracy across muscle groups of various disease and LOI 
states, and not necessarily as an increase in total accuracy. In particular, the methods are capable of 
narrowing the trade-off between sensitivity and specificity. This performance improvement was noted 
in both the simulated and clinical data sets, despite the fact that they were stratified quite differently. 
The improvement is attributed to the fact that at a higher resolution of stratification, the subtle 
differences between LOI states are more easily detected. However, as was seen when using the PD 
classifier, greater stratification resolution increases the demand for training data, and further strata 
would likely lead to diminishing returns. Despite a reliance on training data, PD was able to perform 
quite well, and was found to be more robust when used in conjunction with the AR aggregation 
method. 
A two-stage classifier was also developed so that an optimal configuration could be utilized for 
both disease and LOI characterization. The second stage consisted of a classifier that was re-trained 
using exemplary data specific to the predicted class from the first stage. In the case of simulated data, 
these reduced the number of classes involved in the classifier decision by almost a factor of two, 
resulting in much less complex class boundaries and reduced computational effort. When the 
hierarchical scheme was applied to LOI characterization, it was able to provide an effective 
compromise between categorization accuracy and class resolution. The optimal configuration was 
able to characterize LOI into two clinical states (low and high) at the level of inference with up to 
77% accuracy for simulated data. The hierarchical scheme used for LOI categorization could not be 
validated on clinical data because such data was insufficiently stratified with respect to LOI.  
However, an optimal stratification scheme, consisting of a two-class LOI classifier was shown to 
categorize LOI with 89% accuracy. 
Continuous measures of LOI were found to be impractical due to significant overlap in assigned 
muscles scores across different LOI categories. However, the interpolated scores produced by the 
hierarchical classifier might be useful for visualization purposes.  
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Aggregation measures were evaluated based on how they performed with varying amounts of 
evidence. In particular, as the number of MUPs was increased, the methods improved, with some 
exception. When the quality of the data was good, and confidence in MUP characterizations were 
high, the BR and AB methods were able to take advantage of the information contained in outliers in 
order to make an accurate decision with less evidence (i.e., fewer number of MUPs). However, when 
the quality of evidence is estimated less accurately, these methods were more likely to make an 
erroneous decision, while the conservative averaging technique was able to provide more consistent 
performance. A notable drawback was observed however, where all of the methods presented with a 
performance 'dip' as the amount of evidence increased to 25 MUPs. This 'dip' was only observed in 
cases where high levels of confusion were thought to exist within the MUP characterizations, rather 
than highly confident diagnostically relevant outliers. Further study is required to determine how 
additional evidence would affect the methods under these conditions. In general, however, none of the 
aggregation methods were found to be significantly better or worse than the others. In fact, they 
behave as expected and it is therefore difficult to draw a particular conclusion or recommendation. In 
order to balance the compromising effects of AR with the slightly higher accuracy of BR, it seems 
logical to select one of either WMLO or AB for implementation purposes. Since level of risk 
(reliance on information contained in outliers) allowed by AB can be varied by the choice the of λ 
parameter (see equation 3.3 and equation 3.4), it is the logical choice, giving the decision maker the 
ability to moderate the risk level as necessary. 
In general, the ability to characterize neuromuscular disease was very promising, despite that fact 
that feature distributions plots indicate considerable overlap and non-Gaussian probability densities. 
These findings further support conclusions reached by several authors  (Pino, 2009; Pino et al., 2010; 
Pino et al., 2008; Hamilton-Wright et al., 2010; Pfeiffer and Kunze, 1995) with regards to the 
advantages of probabilistic muscle characterization. In particular, the use of multivariate statistics and 
pattern recognition techniques is able to provide a robust framework to detect neuromuscular 
disorders. By aggregating evidence obtained from multiple statistical samplings of a muscle, an 
accurate inference can be made. Further, it is possible to transparently explain the findings in a 
manner that is consistent with a subjective approach. A significant focus of this work was to 
understand and describe the behavior of various aggregation methods that were analogous to certain 
human decision-making paradigms. Such understanding provides critical insight into the selection of 
such techniques when considering which method to include in a CDSS framework. Ultimately, 
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however, only general guidelines can be made at this point because the methods are greatly dependent 
on factors such as the quality, and availability of data. Further, an appropriate method should be 
selected to meet the specific goals of the decision: namely, a method being used to detect disease 
should use the appropriate level of conservatism depending on the costs associated with type I or type 
II errors. Likewise, when detecting LOI, it might be more reasonable to use a conservative approach 
rather than risking the chance of incorrectly identifying the severity of a disease. 
The intention of this work was not to produce a specific recipe for success in disease 
characterization. Rather, the objectives were to understand the behaviors of the aggregation methods 
and the conditions for which each classifier and aggregation method was optimally suited. In doing 
so, it was found that LDA performed better than PD in terms of accuracy, but not by a large degree. 
This is likely due to the fact that the simplistic nature of LDA makes it better at estimating 
conditional probability with fewer data samples, but the validity of such a statement is likely highly 
dependent on the underlying distributions of the training data. In particular, LDA performs optimally 
when the classes obey a Gaussian distribution. The features presented in this thesis are clearly not 
Gaussian, but despite this LDA was able to perform quite well. On the other hand, PD was able to 
perform comparably under a variety of conditions. The extent to which PD’s performance depends on 
the amount of training data available is not clear. Future work should assess the performance of PD as 
a function of the amount of training data, to determine if further improvements can be made, and 
whether or not there are further gains in using hierarchical methods. 
As a general recommendation based on this work, the author suggests that PD is still the best 
classifier for use in a CDSS, mainly because of its transparency. However, LDA might be more 
appropriate in the second stage as an LOI classifier, because an explanation of these results is not as 
high of a priority. However, if transparency were desired, than attempts could be made to reduce the 
number of features used by LDA to perhaps two or three, allowing for easy visualization. 
Future Work 
In addition to the suggestions for future work already made, there are several questions that were not 
addressed by this work. The first of which has to do with the behaviors of aggregation measures. 
Aggregation measure behavior was only assessed in terms of accuracy thus far. While methods were 
considered for continuous LOI correlation, there was no emphasis on how the various methods 
estimate confidence. The ability to accurately report confidence is necessary for a CDSS, and the 
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paradigm used to arrive at a decision must be chosen based on the level of conservatism required. It 
would be useful to assess whether any particular aggregation method offers a more accurate estimate 
of conditional probability. Although there are methods to obtain well-calibrated confidence scores 
that represent true conditional probabilities (Pino, 2009), such calibration is cumbersome and 
undesirable in most circumstances. Thus it would be prudent to select an aggregation method that 
minimizes the need for calibration. 
The methods centered on data stratification attempt to better represent variations due to different 
levels of LOI in the training set. However a radically different approach may be to attempt to purify 
the training data. Since it is well known that MUPs of all categories can be found within a particular 
set of data, one approach might be to cluster the training set in order to maximize the differences 
between classes. This would essentially ‘purify’ the feature distributions by increasing separation, 
allowing for higher estimates of confidence. Furthermore, in cases where further stratification of the 
data by an expert into LOI groups was unavailable, a clustering approach might be able to detect and 
label subtle changes that can be attributed to different levels of LOI. At this time, it is unclear how 
such techniques would be used, as clusters would be unlabeled and unordered, and future 






A.1 The Inverse Logistic Function (logit) 
The logit of a number p on the interval (0, 1) is given by: 
                                    
When p is a probability, then the term p/(1 - p) is defined as the odds. Under this condition, the 
following results: 
1. The logit of a probability is the logarithm of its odds: 
              
 
   
         
2. The logarithm of an odds ratio (between two probabilities) can be expressed as the difference 
between their logits: 
    
  
    
  
    
      
  
    
      
  
    
                                 
A.2 Bayes’ Theorem Expressed in logits: 
Bayes’ theorem is given by: 
                     
                     
 
   
                 
 
   
 
 
   
      
  
 
      
and can be re-expressed in terms of log-odds as: 
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When expressed in this way, it can be seen that Bayes’ Theorem is additive with respect to each 
piece of evidence (MUP conditional probability), and the weight (significance) of each piece of 




Example of a CDSS 
This appendix provides screenshots of a CDSS based on probabilistic muscle characterizations. The 
figures illustrate the advantages of the probabilistic muscle characterization frameworks proposed in 
(Pino, 2009), namely its ability to explain how each MUP template contributes to a muscle 
characterization and to explore the rationale for this contribution.  The methods depicted herein allow 
a decision maker to 'drill down' from high levels of abstraction to detailed explanations.  
Figures B-1 and B-2 provide visualizations related to MUP characterizations obtained using PD 
based estimates of conditional probability.  Figure B-2 presents individual MUP characterizations as 
small pie charts, each of which is shown to contribute to the overall muscle characterization and level 
of involvement shown on the right.  The muscle characterization scores and involvement percentages 
(using BR and AR, respectively) for each category are represented by large pie charts.  Figure B-2 
shows the feature events that underlie a single MUP characterization.  The plots on the bottom left 
provide a visual interpretation of the rules generated by PD.  Each shape represents a discrete feature 
value (low (L), medium (M) or high (H)), and shapes stacked along the same vertical line represent 
feature values that occurred together as an nth order pattern.  Patterns for or against each category are 
displayed with their x-position reflecting the level of assertion or refutation provided by the 
respective rule.  The solid red bars represent the combined assertion across all rules for a category.  In 
this case, the evidence suggests that the muscle from which the MUPT was detected is likely 
myopathic, but also possesses normal and neurogenic characteristics.  This confusion is driven by the 
presence of rules that provide evidence both for and against the myopathic and neurogenic categories. 
Generally, higher order patterns provide a higher weight of evidence and thus form the basis of the 
decision, in this case showing strong support for the myopathic category and strong refutation of the 
neurogenic category. A second order rule is also present in both the myopathic and neurogenic cases, 
providing contrary evidence to the higher order rule, but to a much lesser degree. The amount of 
evidence is less convincing for the normal category (shown by lower assertion values), but the 
presence of two separate rules bring the overall assertion further to the left. The overall 
characterization is still myopathic, but not with a very high level of confidence given the conflicting 
evidence. In Figure B-2, in the right column are plots of the distributions of the values for each 
feature.  The three bins used for quantization (L, M, H) are demarcated, and green and red bars 
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represent the normal and abnormal ranges for each feature value.  The white bar and plot represent 
the feature value and distribution of feature values for the MUP template and MUP template set, 
respectively.  Figures B-1 and B-2 again demonstrate the ability of the probabilistic methods to 
provide a quantitative overall muscle characterization complete with a measure of confidence and the 
ability to see the distribution of MUP characterizations as well as  the ability to ‘drill down’ into the 
details of the individual MUP characterizations. These examples demonstrate the advantages of using 
transparent decision support systems for QEMG. 
 
 
Figure B-1: Probabilistic Muscle Characterization: Small pie charts at left represent individual 
MUP characterizations.  Large pie chart at top right represents muscle characterization and 




Figure B-2: Probabilistic Muscle Characterization: Details of a specific MUP characterization 
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